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I. Abbreviations 
 
ADP   adenosindiphosphate 
BSA   bovine serum albumin 
DEP   diesel exhaust particles 
EDTA   ethylenediaminetetraacetic acid 
FITC   fluorescein isothiocyanate 
HSA   human serum albumin 
LPS   lipopolysaccharide 
MSA   mouse serum albumin 
MWNT multi-walled carbon nanotubes 
PBS phosphate-buffered saline 
PdI polydispersity index 
PM particulate matter 
PPP platelet-poor plasma 
PRP platelet-rich plasma 
PSGL-1 P-selectin glycoprotein ligand-1 
ROS   reactive oxygen species 
SWNT single-walled carbon nanotubes  
TF   tissue factor 
TFPI   tissue factor pathway inhibitor 
vWF    von Willebrand factor 
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II. Introduction 
 
1. Overview 
Nanoparticles are particles with length scales under 100 nanometres (Lewinski et al. 
2008). Nanoparticles always existed in our ambient nature, but they have received a 
substantial boost of interest in the last 50 years with the emergence of nanotechnology. 
Since then, nanotechnology has grown into a prominent industry and hundreds of 
different variants of nanomaterials and nanotech-based products are now commercially 
available (Maynard and Rejeski 2009).  
The classification of nanoparticles as a new entity is justified by their 
physicochemical properties, which are different from the bulk material and the atoms 
and molecules from which they are built up. Although the unique physicochemical 
properties of manufactured nanoparticles enable the improvement of novel applications, 
they might also cause unusual types of interactions with biological materials and toxic 
effects not yet experienced.  
Nanoparticles can come in contact with the human body through inhalation, 
ingestion, dermal deposition, but also through injection for medical applications. 
Nanoparticles, having entered the body, can translocate into the systemic blood 
circulation, reach various remote organs, and may affect their function. The significance 
of this phenomenon is underlined by previous epidemiological studies identifying 
ambient nano-sized particles as a major contributor to adverse cardio-respiratory effects 
of air pollution, where impact on haemostasis has been found to play an important role. 
(Oberdorster et al. 2005a, Oberdorster et al. 2005b) 
Haemostasis is an important physiological function of the human body, maintaining 
integrity of blood vessels. Disruption of the vascular integrity, resulting in contact of 
human blood with any surfaces other then the inner wall of the vessels, induces 
thrombus formation to stop bleeding (Ruggeri 2002). A well-known consequence is 
unwanted thrombus formation on the surface of implanted foreign materials in the 
circulation (Gorbet and Sefton 2004). Although nanoparticles are small, they represent a 
very high cumulative surface that might also influence haemostasis.  
The increasing utilisation of nanomaterials in technological and medical applications 
warrants an assessment of the risk of these manufactured materials on human health. 
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The fact that nanoparticles represent a potentially thrombogenic large cumulative 
surface, and knowledge of the prothrombotic effects of ambient nanoparticles, raises the 
question of whether manufactured nanoparticles also influence thrombus formation. 
Although circulating nanoparticles also reach the microcirculation, prothrombotic 
effects of manufactured nanoparticles in the microvasculature have not yet been 
examined. The aim of my dissertation was, therefore, to investigate the effects of 
manufactured nanoparticles on platelet activation and on thrombus formation in small 
arteries and in the microcirculation.   
 
2. Nanoparticles 
 
a) Definitions 
Nanotechnology is a relatively new discipline where some of the definitions are still 
immature. The most often used definitions are listed below: 
 
Nano is derived from the Greek word for dwarf and meaning extremely small. 
In physics, it means 10-9.  
 
Nanoparticles are just defined by size. There are, however different definitions 
in use. All of them share the criteria that nanoparticles should be 
smaller than 100 nm, but differ regarding how many dimensions 
should be considered (Oberdorster et al. 2005a, Lewinski et al. 2008). 
In this dissertation, the following more generalised definition is used:   
Nanoparticles are particles with lengths that range from 1 to 100 
nanometres in two or three dimensions (Lewinski et al. 2008). 
Most of the nanoparticles are spherical particles, but the above 
definition is suitable also for particles that are in one dimension 
bigger than 100 nm such as fibres, tubes, or rods. The best examples 
of such high aspect ratio nanoparticles are carbon nanotubes, which 
have a diameter of a few nanometres and a length of several 
micrometres.  
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Nanotechnology is the engineering and manufacturing of material at the atomic 
and molecular scale.  
 
Manufactured nanoparticles are nanoparticles made by nanotechnology. 
 
b) Types of nanoparticles 
Nanoparticles can be categorized as ambient or manufactured nanoparticles (Table 1).  
Ambient nanoparticles are nano-sized particles found in our environment that are 
generated by natural processes such as fires, volcanoes, sea spray, or erosion. In 
addition, they can originate from anthropogenic sources such as traffic or industry. In 
publications about air pollution, ambient nanoparticles are described as a fraction of 
particulate matter (PM). Particulate matter is categorized by size, where PM10 are 
particles under 10 µm, PM2.5 are particles under 2.5 µm, and PM0.1, also referred to as 
ultrafine particles, are nanoparticles present in the ambient air (Oberdorster et al. 2005a, 
Borm et al. 2006).  
Although biological macromolecules are traditionally not considered as 
nanoparticles, many such molecules match the size criteria of nanoparticles. Thus, 
protein complexes (e.g. ribosome, transferrin), lipoproteins or viruses might be regarded 
as biological nanoparticles. Such biological particles are also recommended for the 
production of hybrid bio-nanoparticles (Douglas and Young 2006, Uchida et al. 2007).  
In contrast to ambient nanoparticles, manufactured nanoparticles are produced 
intentionally by nanotechnology. They can be subcategorized according to their material 
(Table 1) (Oberdorster et al. 2005a, Borm et al. 2006). 
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Table 1. Type of nanoparticles 
Source Subtype Examples 
Ambient 
natural processes (fires, 
volcanoes, sea spray, erosion) 
ultrafine particles, or PM0.1 
industrial processes (traffic, 
industry) 
biological nanoparticles  ribosome, lipoproteins, viruses 
manufactured 
carbon nanoparticles 
carbon black, single-walled carbon 
nanotubes (SWNT), multi-walled 
carbon nanotubes (MWNT), 
fullerenes 
quantum dots 
cadmium selenide, cadmium 
sulfide, indium arsenide, indium 
phosphide 
metal, metal oxide 
nanoparticles 
titanium dioxide, zinc oxide, gold, 
silver, iron oxide, silicium oxide 
organic nanoparticles liposome, gelatine 
hybrid bio-nanoparticles nanoparticles in protein cage 
 
c) Properties 
Nanoscale material is an intermediate between atomic and bulk material. Some of the 
special features of nanomaterials are due to the high surface area-volume ratio (Fig. 1). 
When particles are very small, most of the atoms are on the surface of the particle, 
resulting in a large active surface area with a high chemical reactivity. Another conse-
quence of the high surface area-volume ratio is that the van der Waals forces between 
the relatively large surface areas are high enough to move the small mass nanoparticles 
together, resulting in the formation of agglomerates (Borm et al. 2006). The building of 
agglomerates is further exaggerated in biological fluids exerting high ionic strength and 
physiological pH (Nel et al. 2009). 
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Fig. 1. Inverse relationship between particle size and the percent of surface molecules 
(Nel et al. 2006). 
 
Moreover, materials on the nanoscale can exert properties that are independent of 
the high surface area (Burda et al. 2005). An example is the quantum size effect of 
semiconductor nanocrystals, i.e. variations in electric and optical properties at a size that 
is comparable or smaller then the length scale of electron motion in bulk material (Bohr 
radius). Although the bulk material of quantum dots (cadmium selenide, cadmium 
sulphide, indium arsenide, and indium phosphide) do not exert fluorescent properties, 
nanocrystals of these semiconductors (quantum dots) have a very strong and narrow 
fluorescent signal band upon excitation and the wavelength of emission depends on the 
particle size (Biju et al. 2008). In metallic nanoparticles, surface plasmon resonance can 
be induced, whereby free electrons respond collectively by oscillating in resonance with 
the light wave, resulting in light absorption (Burda et al. 2005). Properties of 
ferromagnetic or ferrimagnetic materials also change at around the size of 10-20 nm, 
resulting in a single magnetic domain that shows superparamagnetic behaviour (Lu et 
al. 2007). Carbon in nanotube form gains outstanding mechanical properties with 
extremely high tensile strength (Kis and Zettl 2008). Carbon nanotubes also have 
peculiar electronic characteristics. Their electronic conductivity depends on the tube 
diameter and the wrapping angle (a measure of the helicity of the tube lattice), with only 
slight differences in these parameters causing a shift from metallic to semiconducting 
properties (Wilder et al. 1998). These examples, although not exhaustive, demonstrate 
why nanoparticles open up many possibilities for innovations in technology. 
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d) Applications 
Based on these unique properties, nanomaterials are already widely used in a diverse 
array of applications including chemistry, environmental engineering, food, clothes, 
personal care products, energy production and storage, optics, information technology, 
and construction materials (Maynard et al. 2006, Maynard and Rejeski 2009). There are 
also many biomedical applications of nanoparticles (Salata 2004). Different types of 
nanoparticle constructs are under development, where drugs are delivered by a 
nanoparticle directly to a target cell, lowering unwanted side effects on other cells 
(Davis et al. 2008). Several such drug-containing nanoparticles are already in medical 
use mainly for cancer therapy (Zhang et al. 2008). Labelled magnetic nanoparticles are 
applied for the visualisation of atherosclerotic plaques or tumours by magnetic 
resonance imaging. These magnetic nanoparticles can also be heated by alternating 
magnetic fields, and thus they can be utilised to kill cancer cells (magnetic hyperthermia 
treatment) (Ito et al. 2005, Lu et al. 2007). Nanotechnology is also used in tissue 
engineering to produce biomaterials with nanostructured surfaces that can be better 
incorporated into living tissue, such as in bone implants (Salata 2004). Other biomedical 
applications of nanoparticles include fluorescent labelling, biodetection of pathogens, 
probing of DNA structures, purification of biological molecules, or phagokinetic studies 
(Salata 2004) (Table 2). 
 
Table 2. Examples of nanoparticle applications already available on the market 
(normal text), or under development (in italics). 
Nanoparticle General applications Medical application 
Carbon 
nanotubes 
- construction materials e.g. in 
sport equipments or in wind 
turbine blades 
- antifouling paints for ships 
- batteries for electronic devices 
- purification of drinking water 
(De Volder et al. 2013) 
- bone implants (Salata 2004) 
- drug delivery 
- near infrared hyperthermia 
therapy 
- gene therapy 
- tissue engineering 
(He et al. 2013) 
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Nanoparticle General applications Medical application 
Metal, metal-
oxide 
nanoparticles 
- transparent sunscreens (contains 
TiO2 or ZnO nanoparticles) 
- self-cleaning windows (Borm et 
al. 2006) 
- surface enhanced Raman 
spectroscopy (Burda et al. 
2005) 
- many food products contain 
TiO2 nanoparticles (Weir et al. 
2012) 
- nanoparticle-based therapeutics 
in preclinical development 
(Zhang et al. 2008) 
Magnetic 
nanoparticles 
- high density data storage 
- magnetically separable 
catalysts 
- magnetic separation of 
biomolecules (Lu et al. 2007) 
  
- contrast agent for magnetic 
resonance imaging 
(superparamagnetic iron oxide 
nanoparticles) (Ittrich et al. 
2013) 
- magnetic hyperthermia 
treatment (Ito et al. 2005) 
- magnetic drug delivery (Lu et 
al. 2007) 
Quantum 
dots 
- different applications of 
bioimaging (Chen and Liang 
2014) 
- quantum dot-LED display 
- solar cells with quantum dots 
(Hardman 2006) 
- photodynamic therapy and 
- radiotherapy of cancer with 
quantum dots (Juzenas et al. 
2008) 
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Nanoparticle General applications Medical application 
Liposomes, 
albumin 
based 
nanoparticles 
Textile processing with 
liposomes (Barani and Montazer 
2008)  
  Several clinically approved 
nanoparticle-based therapeutics, 
e.g. drugs for therapy of cancer, 
HIV infection, multiple 
sclerosis, fungal infections, and 
vaccines (Zhang et al. 2008) 
 
e) Interactions with biological molecules 
Nanoparticles in organisms come into contact with biological molecules, and these 
interactions affect their fate and effects in the body (Lynch and Dawson 2008). Due to 
the relatively high surface area versus the small mass, the van der Waals forces cause 
biological molecules to adhere to the particles. Interestingly, the number and types of 
biomolecule that adhere to the curved nanoparticle surface differ in many cases from 
those which adhere to flat surfaces of the same material (Lynch et al. 2009).  
Nanoparticles in a biological fluid (e.g., plasma) are covered by proteins. This 
organized protein structure that surrounds the nanoparticles is called the protein corona 
(Fig. 2).  
 
 
Fig. 2. Nanoparticle protein corona. Adhesion of proteins to nanoparticles is 
determined by different equilibrium constants (Lynch and Dawson 2008). 
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The composition of the protein corona depends on the proteins surrounding the 
nanoparticles, and on the size and surface properties of the nanoparticles (Lundqvist et 
al. 2008). Additionally, the composition of the protein corona is in continuous exchange 
with the proteins of the environment. First, nanoparticles are covered with proteins that 
are abundant in the solution; later, proteins in lower concentration but with higher 
affinity occupy the nanoparticle surface. Accordingly, it has been shown that 
nanoparticles in plasma first bind albumin and fibrinogen molecules, and then bind 
proteins that are present in lower concentrations in plasma but have higher affinity 
toward nanoparticles, such as apolipoproteins (Cedervall et al. 2007b, Lynch and 
Dawson 2008). In the nanoparticle corona almost all of the plasma proteins can be 
found at different amounts according to the particle surface properties: i.e. albumin, 
fibrinogen, immunoglobulins, proteins of the complement system, apolipoproteins, as 
well as coagulation cascade and acute phase proteins (Lundqvist et al. 2008). As a 
consequence of binding, the conformation and function of adhered proteins can change. 
This can lead to the exposure of new epitopes or alter protein function (Nel et al. 2009). 
Nanoparticles can also induce protein fibrillation, i.e. certain proteins aggregate into 
long, thin fibrils called amyloid structures (Colvin and Kulinowski 2007, Linse et al. 
2007). It is generally perceived that the properties of nanoparticles determine the 
composition of the protein corona. In turn, the composition of the protein corona 
determines the behaviour of nanoparticles in biological systems. The protein corona can 
influence the interaction with receptors, cellular uptake, organ distribution, cell and 
organ functions, and excretion. It has been demonstrated that inhibition of protein 
adhesion by coating nanoparticles with amphiphilic polyethylene glycol molecules leads 
to decreased cellular uptake, longer circulation, and altered biodistribution (Praetner et 
al. 2010, Jokerst et al. 2011). 
Nanoparticles also interact with membrane phospholipids. Adhesion depends on the 
charge of nanoparticles (Verma and Stellacci 2010). It has been shown that 
nanoparticles of negative charge induce local gelation in otherwise fluid bilayers; 
nanoparticles of positive charge induce otherwise gelled membranes to fluidize locally. 
It has been hypothesised that charged nanoparticles alter the tilt angle of the phospho-
choline head group, which is an electric dipole of phosphate and choline. The 
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reorganisation of the phosphocholine head group changes the fluidity of membranes. 
(Wang et al. 2008) 
Nucleic acids bind to nanoparticles as well. Cationic nanoparticles or nanoparticles 
bearing cationic ligands provide highly efficient DNA binding via electrostatic 
interaction. This kind of interaction can be utilised for electrostatic assembly of 
nanoparticles along DNA molecules (Saha et al. 2011). High affinity binding of single-
stranded DNA to SWNT has been used for quantitative detection of SWNT in aqueous 
samples (Mota et al. 2013). 
 
f) Interactions with cells 
Nanoparticles are able to undergo diverse interactions with cells. Nanoparticles can 
adhere to cell surfaces, translocate into cells, and influence cellular functions through 
interactions with cell components (Zhao et al. 2011).   
As described above (section II/2/e), nanoparticles can adhere to proteins and lipid 
macromolecules, which are the main components of cell membranes.  
Cells can internalise nanoparticles by different mechanisms. Larger or aggregated 
nanoparticles are taken up by phagocytosis by specialized cells such as macrophages, 
monocytes, and neutrophils or by macropinocytosis by other cell types. Smaller 
particles can be endocytosed through the formation of endocytic vesicles of different 
sizes by clathrin-mediated (~120 nm), caveolae-mediated (~60 nm), or clathrin/caveolin 
independent (~90 nm) mechanisms (Conner and Schmid 2003, Dobrovolskaia and 
McNeil 2007, Verma and Stellacci 2010) (Fig 3). Moreover, some nanoparticles are 
able to penetrate cell membranes without any active process of the cell (Verma and 
Stellacci 2010).  
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Fig 3. Endocytosis mechanism depends on the size of nanoparticles (Conner and 
Schmid 2003). 
 
Nanoparticles taken up by an active internalisation process of the cell are enclosed in 
endosomes and thus separated from the cytosol. There are, however, several 
mechanisms that lead to the escape of nanoparticles from the endosomes. Internalisation 
of nanoparticles with high aspect ratio such as MWNT, which are relatively long and 
stiff, can lead to disruption of the phagosome (frustrated phagocytosis). Macrophages, 
in an attempt to destroy the carbon nanotubes, release harmful oxygen radicals, and 
hydrolytic enzymes which are deposited in the surrounding medium, leading to chronic 
inflammation (Poland et al. 2008). Amine-modified nanoparticles were also described 
as being able to escape from the lysosomes to the cytoplasm. This phenomenon can be 
explained by the proton sponge hypothesis that states that unsaturated amines on the 
material surface are capable of sequestering protons. The lysosomal proton pump, 
which is responsible for acidification, tries to acidize the lysosome, keeping the pump 
going, and leading to the retention of one Cl– anion and one water molecule for each 
proton that enters the lysosome. Ultimately, this process causes lysosomal swelling and 
rupture, leading to particle deposition in the cytoplasm (Dobrovolskaia and McNeil 
2007, Xia et al. 2008).  
Oxidative stress is thought to play an important role in the mechanisms of 
nanoparticle-induced cytotoxicity. Nanoparticles can generate reactive oxygen species 
(ROS) through redox chemistry or interfere with the ROS production of the cell. The 
excited energy state in a semiconductor nanoparticle leads to the generation of 
superoxide radicals, e.g. titanium dioxide nanoparticles produce ROS upon ultraviolet 
light exposure. Transition metals on the nanomaterial surface (e.g. metal impurities in 
nanotubes) can generate superoxide anions through Fenton chemistry. Nanoparticles can 
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also alter phagocytosis leading to intracellular (proton sponge hypothesis) or 
extracellular release of ROS (frustrated phagocytosis). Furthermore, nanoparticles can 
lodge in mitochondria and interfere with the electron transport chain leading to the 
production of superoxide anions (Nel et al. 2006, Li et al. 2008).  
Nanoparticles can also enter the nucleus either by penetrating the nuclear membrane, 
or being transported through the nuclear pore complexes, or becoming enclosed in the 
nucleus by chance during mitosis. Nanoparticles can cause genotoxic effect through 
ROS production, direct mechanical interference with the mitotic spindle and DNA or 
interaction with nuclear proteins and enzymes (Gonzalez et al. 2008, Singh et al. 2009). 
Nanoparticles at different subcellular locations can interact with macromolecules 
and thus influence cellular functions. 
 
g) Exposure routes, biodistribution, and fate 
Nanoparticles can enter the human body through the skin, respiratory, or gastrointestinal 
tract, or by injection into the circulation (Oberdorster et al. 2005a). The actual exposure 
route depends on the exposure scenario (Fig. 4). Ambient nanoparticles from natural 
sources such as combustion processes enter the human body mainly via inhalation. 
Manufactured nanoparticles can also be inhaled if they get into the air during 
production. Nanoparticles in food or water can get into the body through the 
gastrointestinal tract. Nanoparticles in cosmetics and sun creams come into contact with 
the skin. Nanoparticles can be cleared from these organs, e.g. from the respiratory tract, 
by the mucociliar system, or they might be deposited. Importantly, nanoparticles can 
translocate from these organs into the blood vessels and reach any tissue of the body 
through the systemic circulation. 
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Fig. 4. Confirmed (solid arrow) and potential (dashed arrow) exposure routes of 
nanoparticles in the human body. Nanoparticles can be taken up into the human body 
from the air through the respiratory tract, from food and water through the 
gastrointestinal tract, or they can be deposited from air, water, or clothes onto the skin. 
Nanoparticles might translocate from these organs into the blood, or in medical 
applications they can also be directly injected into the systemic circulation. Circulating 
nanoparticles can reach any organs of the body and be excreted by the kidney, liver, or 
skin. GI tract: gastrointestinal tract, CNS: central nervous system, PNS: peripheral 
nervous system.  (Oberdorster et al. 2005a) 
 
Several experimental studies have shown that a small fraction of inhaled 
nanoparticles, depending on their size, can cross the air-blood barrier in the lungs and 
translocate into the systemic circulation. Kreyling and coworkers have shown that 
depending on particle size about 1-10 % of deposited 192Ir particles translocated from 
the lungs into the blood and deposited in secondary organs, such as liver, spleen, heart, 
and brain (Kreyling et al. 2002). Nemmar and coworkers confirmed this observation in 
a human study. They found that inhaled 99mTc-labelled ultrafine carbon particles pass 
rapidly into the systemic circulation (Nemmar et al. 2002a). The mechanism of 
translocation is supposed to be via pores (Conhaim et al. 1988, Hermans and Bernard 
1999) or by diffusion through the cells of the alveoli (Geiser et al. 2005). Translocation 
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from the lungs was shown for different types of nanoparticles: 192Iridium particles 
(Kreyling et al. 2002), ultrafine particles (Nemmar et al. 2002a), Tc-labelled albumin 
molecules (Nemmar et al. 2001), carbon black (Shimada et al. 2006), gold nanoparticles 
(Lipka et al. 2010), nano-ceria (He et al. 2010), and fullerenes (Naota et al. 2009). 
Another main exposure route is through the gastrointestinal tract. It is estimated that 
1012-1014 fine and ultrafine particles, including mainly silicates and titanium dioxide, 
are ingested per person per day in the Western world (Lomer et al. 2002). Experiments 
in rats and also human studies have shown that TiO2 particles (150–500 nm) taken in via 
food can translocate into the blood and accumulate in the liver and spleen (Jani et al. 
1990, Borm et al. 2006). 
Regarding the contact of nanoparticles with the skin, numerous studies have 
demonstrated that TiO2 or ZnO nanoparticles do not penetrate into or translocate 
through normal skin (Nohynek et al. 2007, Nohynek et al. 2008, Nohynek et al. 2010). 
However, small quantum dots can penetrate broken skin to lodge in other tissues and 
organs (Mortensen et al. 2008). 
In diagnostic or therapeutic medical applications, nanoparticles are directly injected 
into the systemic circulation. Nanoparticles translocated from the respiratory or gastro-
intestinal tract into the systemic circulation or nanoparticles directly injected into the 
bloodstream can reach all the organs of the body and finally pass the microcirculation of 
any tissue (Borm et al. 2006, Geiser and Kreyling 2010). It has been shown that 
circulating nanoparticles can also cross the blood brain barrier and accumulate in the 
brain (Kreuter 2001, Hu and Gao 2010). A special route to the central nervous system is 
the direct pathway of nanoparticles from the nasal airways into the brain through the 
olfactory nerves (Elder et al. 2006).  
The biodistribution of nanoparticles depends on their properties. The main uptake 
organs are the lungs, liver, and spleen. Nanoparticles have different half-lives in the 
body depending on their type and surface modifications, and they are excreted through 
renal or hepatic pathways. The way of excretion depends on size, shape, charge, and 
composition of the nanoparticles. Nanoparticles which are smaller than 6 nm can be 
filtered in the glomerulus and excreted by the kidney in the same way as small 
biological molecules. Interestingly, high aspect ratio nanoparticles, such as carbon 
nanotubes, which have a mean diameter of few nm and lengths in the micrometer range, 
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have been reported to be cleared from the blood also through the renal pathway. The 
other main organ of nanoparticle excretion is the liver, which is able to excrete 
nanoparticles that do not undergo renal clearance. Hepatocytes can take up 
nanoparticles from the blood, and eliminate them via the biliary pathway. For example, 
polystyrene nanoparticles have been found to be eliminated by the hepatic pathway, 
which was mediated by ApoE receptors. Also hepatic Kupffer cells, together with other 
cells of the reticuloendothelial system, contribute to the elimination of nanoparticles, 
mainly by degradation processes. On the other hand, nanoparticles such as quantum 
dots, which can not be degraded, deposit in the phagocytes, leading to long-term 
retention of these nanoparticles in the body. (Choi et al. 2007, Hagens et al. 2007, 
Longmire et al. 2008, Landsiedel et al. 2012)  
 
3. Thrombus formation 
Haemostasis is an essential physiological function maintaining the integrity of vessels 
based on a well-tuned interplay between endothelial cells, platelets, and the coagulation 
system. Haemostatic processes are able to stop bleeding from injured vessels by platelet 
plug formation and blood coagulation. On the other hand, pathological thrombus 
formation may induce thromboembolic diseases.  
 
Vascular injury 
Intact endothelial cells provide a non-thrombogenic surface to which neither platelets 
nor fibrin mesh can adhere (Fig 5). Additionally, endothelial cells actively inhibit 
thrombus formation. They produce prostacyclin and nitric oxide, which both suppress 
platelet activation. Endothelial cells also express CD39, an ecto-ADPase that blocks 
adenosindiphosphate (ADP) dependent secondary platelet activation. Heparan sulphate 
and thrombomodulin-protein C complex on the surface of endothelial cells, as well as 
the endothelial production of tissue factor pathway inhibitor (TFPI), inhibit the 
coagulation system. Finally, the production of plasminogen activators (tissue 
plasminogen activator and urokinase-type plasminogen activator) leads to lysis of 
erroneously generated thrombi (Ruggeri 2002). 
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Fig 5. A. Vascular patency. Healthy endothelial cells inhibit thrombus formation. 
Prostacyclin (PGI2), nitric monoxide (NO), and ecto-ADPase (CD39) suppress platelet 
activation. Thrombomodulin (TM), heparan sulphate (HS), and tissue plasminogen 
activator (TPA) counteract the coagulation process. B. Response to injury. Loss of 
antithrombogenic endothelial cells and interaction of platelets and plasma proteins with 
prothrombotic constituents of the subendothelial matrix induces thrombus formation: 
generation of a platelet plug and a fibrin mesh. Modified after Ruggeri at al. (Ruggeri 
2002).  
 
At the site of vascular injury, the loss of antithrombogenic endothelial cells and the 
contact with the denuded subendothelial matrix evolve the formation of a platelet plug 
and initiate the coagulation cascade (Fig 5). The subendothelial matrix is, in contrast to 
endothelial cells, highly thrombogenic. Moreover, von Willebrand factor (vWF), the 
main ligand of platelet tethering, immediately deposits from plasma onto the denuded 
subendothelial layer. The interaction between subendothelial matrix proteins and 
platelets lead to the adhesion and activation of platelets. At the same time, tissue factor 
(TF) expressed on the surface of subendothelial cells initiates the coagulation process. 
During thrombus formation, platelets form a plug and the coagulation cascade forms a 
fibrin mesh, and these two processes aid one another (Ruggeri 2002). 
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Platelet adhesion and initial platelet activation 
Platelets are small (2-5 µm) anuclear cell fragments with armature for adhesion and 
aggregation (Broos et al. 2012). Adhesion is a multistep process between elements of 
the subendothelial matrix of the vessel wall and the receptors of platelets (Fig 6). 
Platelets first tether through glycoprotein GPIb-V-IX to vWF immobilized on collagen 
fibres. This adhesive interaction is rapidly reversible and does not readily support stable 
platelet adhesion. However, the resulting rolling and deceleration of platelets allows the 
interaction of the two major collagen receptors GPVI and integrin α2β1 with the 
subendothelial matrix resulting in firm adhesion and platelet activation. (Ruggeri 2002, 
Varga-Szabo et al. 2008, Nuyttens et al. 2011) 
 
 
Fig. 6. Formation of a platelet plug on the denuded subendothelial matrix. Platelets 
tether to vWF via GP-Ib-V-IX receptors. Interaction of platelet receptors with proteins 
of the subendothelial matrix induces platelet adhesion. Activation of αIIbβ3 receptors 
leads to aggregation of platelets bridged by fibrinogen molecules. (Jackson et al. 2000).  
 
Collagen-GPVI and vWF-GPIb-V-IX interactions are the key initiators of platelet 
activation (Fig. 7). Signal transduction through phospholipase C γ2 results in the release 
of secondary activation molecules, integrin activation, and procoagulant changes in 
platelets (Li et al. 2010). 
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Fig. 7. Platelet signalling. Exposure to the subendothelial matrix activates platelets: 
collagen-GPVI, collagen-α2β1, and vWF-GPIb-V-IX interactions activate phospholipase 
Cγ2 (PLCγ2) inducing the formation of inositol triphosphate (IP3) and diacylglycerol 
(DAG) second messengers. IP3 mobilise Ca2+ from intracellular stores through inositol 
triphosphate receptor (IP3R) which subsequently leads also to Ca2+ influx by store 
operated calcium entry (SOCE). Ca2+ and DAG activate calcium and DAG regulated 
guanine nucleotide exchange factor 1 (CalDEG-GEFI). This signal transduction results 
in degranulation, synthesis of thromboxane A2 (TXA2) by phospholipase A2 (PLA2), and 
inside-out activation of αIIbβ3 receptors. Platelet activation through second messengers 
and thrombin: ADP receptor P2Y1, TXA2 receptor TP, and thrombin receptors PAR1/4 
activate PLCβ2, which further exaggerates the platelet activation. ADP can also bind to 
P2Y12 receptor, which blocks the synthesis of inhibitory cAMP molecules. Endothelial 
cells inhibit platelets: Prostacyclin (PGI2) binds to prostacyclin receptor (IP) and 
activates adenylate cyclase (AC) leading to increased cyclic adenosine monophosphate 
(cAMP) level. Nitric monoxide (NO) increases intracellular cyclic guanosine 
monophosphate (cGMP) through the soluble guanylate cyclase (sGC). Increased levels 
of cAMP and cGMP suppress platelet activation. Slightly modified after Broos et al. 
(Broos et al. 2012).  
DOI:10.14753/SE.2016.1824
 24 
Secondary platelet activation 
After adhesion and activation of adhered platelets, secondary platelet activation 
molecules are released (Fig. 7). ADP and serotonin are released by degranulation of 
dense-granules upon activation of platelets. In contrast, thromboxane A2 is de novo 
synthesized from phospholipids. Thrombin, not a secondary platelet activator, is 
generated in the coagulation cascade and besides having a pivotal role in coagulation, 
contributes also to activation of platelets. All of these activator molecules act through 
G-protein coupled receptors. These autocrine and paracrine signals further excite 
already activated platelets and amplify the thrombus formation process by activating 
and recruiting other platelets to the growing thrombus. (Li et al. 2010, Broos et al. 2012) 
 
Platelet aggregation 
Aggregation means the binding of platelets to each other, leading to a growing 
thrombus and finally to a haemostatic platelet plug. Platelets adhere to each other by 
binding to both sides of a fibrinogen molecule through αIIbβ3 receptors (Fig. 6). In 
resting platelets, the receptor only has a low affinity to fibrinogen, but the affinity 
dramatically increases upon platelet activation. This change in fibrinogen activity 
requires an inside-out activation of the αIIbβ3 integrin receptor (Fig 7). The activated 
αIIbβ3 receptor is able to bind fibrinogen, leading to the aggregation of platelets. Ligand 
binding of the αIIbβ3 receptor also induces signalling events, i.e. outside-in signalling 
leads to platelet spreading, granule secretion, and clot retraction. (Ruggeri 2002, 
Jackson 2007, Li et al. 2010). 
 
Procoagulant changes in platelets 
Platelet activation also induces procoagulant changes in platelets. Activation of 
scramblase leads to the exposure of negatively charged phosphatidylserine molecules on 
the plasma membrane, providing a platform for the coagulation cascade. Vitamin K-
dependent clotting factors in the presence of Ca2+ can bind to the platelet plasma 
membrane. In these compartments, coagulation factors can build complexes that   
accelerate the speed of enzymatic reactions by 105-107 times. In addition, activated 
platelets produce procoagulant microparticles that further increase the active surface for 
the coagulation process (Machovich 2006, Tanaka et al. 2009, Broos et al. 2012, 
Clemetson 2012). 
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Formation of platelet-leukocyte complexes 
Activation of platelets does not only induce platelet-platelet adhesion but also the 
formation of heterotypic platelet-leukocyte aggregates (Fig. 8). Platelets can form 
complexes with granulocytes, monocytes, and with subsets of lymphocytes. These 
interactions play an important role in platelet-dependent leukocyte recruitment and also 
in the augmentation of thrombus formation.  
 
 
Fig. 8. Platelet-leukocyte adhesion. Tethering of platelets to leukocytes through 
P-selectin and PSGL-1 induces activation of αMβ2 receptors. Binding of activated αMβ2 
to αIIbβ3 through fibrinogen and to GPIb-V-IX directly leads to firm adhesion. Modified 
after Ley at al. (Ley 2011) 
 
The initial adhesion of platelets to leukocytes is mediated by P-selectin on platelets 
and P-selectin glycoprotein ligand-1 (PSGL-1) on leukocytes. Ligation of PSGL-1 leads 
to Src family kinase-dependent signalling that results in conformational change of 
leukocyte β2 integrins and also induces delayed responses in leukocytes by the 
activation of nuclear factor κB and the transcription of proinflammatory molecules 
(Totani and Evangelista 2010). On the other hand, the loose connection between P-
selectin and PSGL-1 holds platelets and leukocytes close to each other, enabling the 
formation of firm connections, and also activates leukocyte integrins necessary for the 
strong adhesion. Firm platelet-leukocyte adhesion is mediated mainly due to the 
formation of a fibrinogen bridge between αIIbβ3 on platelets and macrophage 1-antigen 
(αMβ2 integrin) on leukocytes, and due to the direct interaction of leukocyte macrophage 
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1-antigen (αMβ2 integrin) and GPIb-V-IX receptor of platelets (May et al. 2007). These 
interactions recruit leukocytes to the site of the thrombus formation. In these heterotypic 
conjugates, the interaction of platelet P-selectin with leukocyte PSGL-1 and platelet 
CD40 ligand with leukocyte CD40 induces TF expression of leukocytes contributing to 
initiation of the coagulation cascade and consequently to fibrin production (Cerletti et 
al. 2012). Moreover, activated neutrophils recruited to the thrombus produce neutrophil 
extracellular traps. Neutrophil extracellular traps serve as a scaffold primarily composed 
of extracellular DNA fibres, which are able to trap pathogens circulating in blood. 
Neutrophil extracellular trap fibres also contribute significantly to thrombus formation 
by adhering and activating platelets as well as by stimulating fibrin formation (Fuchs et 
al. 2012). 
  
Initiation of the coagulation cascade 
At the same time as platelet plug formation, blood coagulation factors become activated 
at the sites of vascular lesions. The initial step of the coagulation cascade (Fig. 9) is 
triggered by the interaction of activated factor VII plasma protein with subendothelial 
TF at the site of vascular injury (extrinsic pathway). The activated factor VII-TF 
complex cleaves factor X. Activated factor X together with activated cofactor V cleaves 
prothrombin to thrombin. In the initial phase of coagulation, activated factor X 
generates just a trace amount of thrombin. There are two main inhibitors of the initiation 
of the coagulation cascade: TFPI blocking factor X, and antithrombin III blocking factor 
X and thrombin. For the initialization of the coagulation cascade, the TF concentration 
has to be high enough to overcome the barrier given by TFPI and antithrombin III in 
order to propagate the coagulation reaction. This mechanism prevents the false 
activation of the coagulation cascade (Tanaka et al. 2009). 
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Fig. 9. Initiation and propagation of the coagulation cascade. The coagulation cascade 
is triggered by the interaction of TF with factor VII. Activated factor VII-TF complex 
(fVIIa/TF) leads to the activation of factor X (fXa) and factor II (fIIa). The propagation 
of the coagulation cascade is due to a positive feedback loop involving the activation of 
factor XII (fXIIa), XI (fXIa), X (fXa), II (fIIa), and cofactor VIII (fVIIIa) and V (fVa) on 
activated platelets. Activated factor II cleaves fibrin, resulting in fibrin polymerisation. 
Activated factor XIII (fXIIIa) strengthens the fibrin mesh. Antithrombin III (AT) and 
TFPI are inhibitors of the coagulation cascade. Slightly modified after Tanaka et al. 
(Tanaka et al. 2009) 
 
Propagation of thrombin production 
After initiation of the coagulation cascade, thrombin generation is further exaggerated 
due to positive feedback loops involving coagulation factors of the intrinsic pathway 
(Fig 9). Thrombin activates factor XI, VIII, and V. Activated factor XI mediates the 
activation of factor IX. Activated factor IX together with activated cofactor VIII 
mediates the cleavage of factor X leading to thrombin generation. Thus, thrombin 
exaggerates its own production by activating serine proteases of the intrinsic pathway. 
Thrombin has a central role in haemostasis: it mediates the generation and stabilisation 
of the fibrin mesh and it is also a very potent platelet activator.  
 
Contact activation  
Coagulation might also be initiated in an alternative way due to contact activation. The 
biological relevance of this kind of activation has not been fully elucidated, but this 
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mechanism is relevant to thrombus formation upon the interaction of foreign materials 
with blood. This phenomenon is also widely utilised in the measurement of the 
activated partial thromboplastin time when silica or kaolin particles are added to blood 
to initiate the intrinsic coagulation. The contact system consists of factor XII, plasma 
kallikrein, as well as the cofactor high-molecular-weight-kininogen that assembles on 
negatively charged surfaces. When particles with a negatively charged solid surface are 
incubated with blood, factor XII is able to become activated non-enzymatically. 
Alternatively, plasma kallikrein can cleave and activate the surface-bound factor XII. 
Activated factor XII also cleaves prekallikrein to kallikrein, resulting in a positive 
amplification loop. Activated factor XII activates factor XI and thus initiates the 
intrinsic pathway of the coagulation process (Maas and Renne 2012).  
 
Fibrin mesh 
Once thrombin is generated, it cleaves fibrinogen molecules, leading to the release of 
fibrin monomers. These monomers aggregate spontaneously in a regular array, forming 
a fibrin clot. In addition to fibrin formation, thrombin activates factor XIII, a highly 
specific transglutaminase that introduces cross-links composed of covalent bonds 
between the glutamines and lysines in the fibrin monomers.  
 
Fibrinolysis 
Erroneously or excessively produced fibrin mesh can be degraded by fibrinolysis. At 
first plasminogen, the proenzyme of plasmin, binds to the lysine side chains of the fibrin 
mesh. This interaction leads to a conformational change of plasminogen molecules, 
enabling cleavage of plasminogen by plasminogen activators (tissue plasminogen 
activator and urokinase-type plasminogen activator). The generated plasmin cleaves 
fibrin into soluble fibrin degradation products, making more and more lysine side chains 
available where new plasminogen molecules can adhere and become activated. The 
fibrinolysis is controlled by plasminogen activator inhibitor-1, plasmin inhibitor and 
trombin activatable fibrinolysis inhibitor. The latter inhibits fibrinolysis by removing 
lysine side chains from the fibrin mesh. (Machovich 2006, Schaller and Gerber 2011, 
Foley et al. 2013) 
 
DOI:10.14753/SE.2016.1824
 29 
Thrombus formation in the microcirculation 
Disturbances in haemostasis can also occur in the microcirculation, inducing alteration 
of blood flow in tissues. Augmented microcirculatory thrombus formation has been 
implicated in the pathophysiology of sepsis, disseminated intravascular coagulation, and 
multiple organ dysfunctions (Gando 2010, Semeraro et al. 2012). Microvascular 
thrombosis also plays an important role in thrombotic microangiopathies, which 
comprise a spectrum of diseases such as typical and atypical haemolytic uremic 
syndrome, thrombotic thrombocytopenic purpura, antiphospholipid syndrome, 
paroxismal nocturnal haemoglobinuria, malignant hypertension, drugs or systemic 
autoimmune diseases or antibody-mediated rejection (Benz and Amann 2010). 
 
4. Nanoparticles and thrombus formation 
 
a) Thrombus formation on foreign surfaces 
There is a great deal of information about the interaction between blood and foreign 
material devices such as oxygenators, plasmapheresis equipment, hemodialysers, 
catheters, stents, vascular grafts, or heart valves. Thrombosis and embolization are well-
known complications of these cardiovascular devices. The interaction of blood with 
foreign surfaces induces thrombus formation by a combination of several mechanisms, 
involving the coagulation system, platelets, the complement system, and leukocytes 
(Gorbet and Sefton 2004)  
Upon interaction with blood, biomaterials are immediately covered by plasma 
proteins. Among these proteins are fibrinogen, vWF, factor XII, high molecular weight 
kininogen, C3 complement, and IgG (Ekdahl et al. 2011).  
Factor XII becomes non-enzymatically activated upon adhesion onto negatively 
charged surfaces and initiates the coagulation cascade (Gorbet and Sefton 2004, Vogler 
and Siedlecki 2009). 
Platelets can adhere to foreign materials mediated by αIIbβ3 or GPIb-V-IX receptors 
binding to fibrinogen or vWF adhering to the surface of biomaterials. Adhesion leads to 
platelet activation. However, the interaction with biomaterials often induces platelet 
activation without adhesion, which is characterised by a decreased platelet count due to 
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the removal of activated platelets from the circulation. In the presence of cardiovascular 
devices, platelets also adhere to leukocytes and induce the formation of platelet-
leukocyte aggregates (Mickelson et al. 1996, Bonomini et al. 1999, Gorbet and Sefton 
2004) (see also section II/3). The amount of platelet-leukocyte aggregates can also be 
considered as a parameter for biocompatibility (Gorbet and Sefton 2004). 
The complement cascade, which is part of the innate immune system, also 
contributes to the thrombus formation on biomaterials. The complement cascade results 
in the formation of the terminal C5b-9 complement complex that can be incorporated 
into platelet membranes inducing platelet activation. Platelets are also activated by the 
interaction of C1q and C3a ligands with their platelet receptors. (Gorbet and Sefton 
2004, Markiewski et al. 2007, Ekdahl et al. 2011) 
Leukocytes can also adhere to the surface of foreign materials. Upon adhesion and 
due to complement activation, leukocytes express TF. Interaction of TF with factor VII 
initiates the extrinsic pathway of coagulation. Adhered leukocytes also contribute to the 
recruitment of platelets by binding platelets to biomaterials through platelet-leukocyte 
interactions (Gorbet and Sefton 2004, Vogler and Siedlecki 2009). 
 
b) Epidemiology of particulate matter-associated diseases 
Relevant information about the toxicity of nanoparticles comes from the investigation of 
the detrimental effect of air pollution on the human body. Although air pollution is 
composed not just of nanosized particles, but also larger particulate matter, gaseous and 
liquid components, this knowledge gives some clues about the possible effects of 
nanoparticles. 
There is a well-known epidemiological association between air pollution and 
cardiovascular or pulmonary diseases (Brook et al. 2010). The detrimental health effects 
of air pollution were first realised in the 20th century after major incidents involving 
acute air pollution (Meuse Valley, Belgium 1930; Donora, USA 1948; and Greater 
London, UK 1952,) caused sudden deaths, increased illness, and hospital admissions 
(Simkhovich et al. 2008).  
Further investigations revealed that the particulate matter fraction of air pollution is 
the major contributor to these toxic effects. A number of epidemiological studies have 
demonstrated the close relationship between particulate matter levels and 
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cardiopulmonary mortality both in short and long-term studies. Overall evidence from 
meta-analysis of about 100 research papers since the early 1990s and recent 
comprehensive analysis of large number multicity studies assume that a short-term (1 to 
5 days) 10 µg/m3 elevation of PM2.5 results in an ~1% increase in mortality (Pope and 
Dockery 2006, Samoli et al. 2008, Brook et al. 2010, Emmerechts and Hoylaerts 2012). 
Long-term prospective cohort studies have provided more evidence about the health 
effects of particulate matter. The Harvard Six Cities Study investigated about 8000 
persons over 14-16 years (Dockery et al. 1993), the American Cancer Society study 
analysed data from more than 500,000 adults over 16 years (Pope et al. 2002, Pope et al. 
2004, Franchini and Mannucci 2012) and recent large cohort studies of 13.2 million US 
Medicare participants were analysed for the time period 2000 to 2005. The overall 
evidence from the cohort studies show on average 10% increase for all case mortality 
per 10 µg/m3 elevation in long-term PM2.5 exposure. The cardiovascular mortality risk 
ranges from 3% to 76% in the different cohort studies (Brook et al. 2010).  
The role of the nano-sized fraction in particulate matter induced detrimental effects 
has been gathered from studies collecting data at the source of combustion-derived 
particles. Ultrafine particles generated by combustion-related processes have a very 
short life (minutes to hours) and rapidly grow to form a larger complex. Therefore, 
ultrafine particulate matter concentration is at its highest near the source of primary 
particles, such as in the vicinity of busy roads. Interestingly, Peters et al. found in a 
survey of 691 patients a correlation between exposure to traffic and the onset of a 
myocardial infarction within one hour afterwards (Peters et al. 2001, Peters et al. 2004). 
An association was also found between short-term exposure to ultrafine particles and 
hospital admissions for stroke (Andersen et al. 2010). A linear relationship was 
described between the distance from major traffic roads and the risk of deep vein 
thrombosis (Baccarelli et al. 2009), indicating the role of ultrafine particles in this 
process. 
There are also epidemiological data that substantiate the influence of air pollution on 
haemostasis (Emmerechts and Hoylaerts 2012). A positive association was found 
between particulate matter exposure and plasma fibrinogen concentration, plasminogen 
activator inhibitor-1 level, and changes of coagulation tests towards hypercoagulability 
(Pekkanen et al. 2000, Su et al. 2006, Baccarelli et al. 2007, Chuang et al. 2007, Bigert 
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et al. 2008). Particulate matter exposure is also associated with platelet activation. 
Chronic inhalation of particulate matter emitted from biomass burning during household 
cooking in India was shown to induce platelet activation (increased CD62P expression) 
and to increase the amount of platelet-leukocyte aggregates (Ray et al. 2006). Positive 
associations were found between soluble P-selectin (shedding after platelet activation) 
and ambient ultrafine particles (Delfino et al. 2008). Also an immediate increase of a 
plasma soluble CD40 ligand and a decrease in platelet count was found to be associated 
with ultrafine particles (Ruckerl et al. 2007).  
 
c) Particulate matter and thrombus formation 
To find out how inhaled particulate matter induces detrimental cardiovascular effects 
several experimental studies have been carried out. Inhaled particles have been found to 
deposit in the lungs and to induce the production of inflammatory mediators. Based on 
these findings, the first (classical) hypothesis was that the release of inflammatory 
agents from the lungs into the blood circulation alters the cardiovascular system or 
haemostasis (Fig. 10) (Brook et al. 2004, Mills et al. 2009). 
The role of inflammatory mediators in inducing prothrombotic effects is supported 
by experiments in which mice were intratracheally exposed to particulate matter. These 
studies observed shortened bleeding time and increased thrombus formation 24 hours 
after application (Mutlu et al. 2007). The prothrombotic effect was attributed to an IL-6-
dependent increased activity of the coagulation cascade, and a tumour necrosis factor 
alpha-dependent decreased fibrinolysis due to increased plasminogen activator 
inhibitor-1 activity (Mutlu et al. 2007, Budinger et al. 2011). Also controlled human 
exposure to diesel exhaust particles (DEP) was shown to reduce the release of 
endothelial tissue plasminogen activator (Mills et al. 2005, Mills et al. 2007). 
Furthermore, increased TF expression was demonstrated upon incubation of different 
cells with particulate matter in vitro and in the aorta after long-term exposure to 
particulate matter in vivo (Gilmour et al. 2005, Sun et al. 2008).  
 
DOI:10.14753/SE.2016.1824
 33 
 
Fig. 10. Classical and alternative pathways through which airborne nanoparticles 
induce cardiovascular effects. Classical pathway: Nanoparticles deposited in the lung 
induce oxidative stress through chemically active organic or metal compounds given on 
the surface of nanoparticles or through activation of neutrophils and macrophages. In 
this way they initiate the production of inflammatory mediators from macrophages and 
alveolar epithelial cells, which are released into the systemic circulation and induce 
cardiovascular effects. Alternative pathway: Nanoparticles translocate from the lungs 
through the alveolar epithelium into the blood circulation, where they alter 
cardiovascular functions. (Mills et al. 2009) 
 
In further epidemiological studies about the detrimental effects of particulate matter, 
the important role of its ultrafine fraction has been indicated. Knowing that nano-sized 
particles are able to translocate from the lungs into the blood (see section II/2/g), an 
alternative hypothesis was suggested emphasizing that translocated ultrafine particles 
can reach remote tissues via the circulation and influence organ functions directly (Fig. 
10) (Brook et al. 2004, Mills et al. 2009). 
The first experimental findings supporting the alternative hypothesis that 
intratracheally administered nanoparticles are able to augment thrombus formation were 
published by Nemmar et al. The authors demonstrated in an in vivo hamster model that 
intratracheally instilled or intravenously injected amine-modified polystyrene 
nanoparticles activate platelets and enhance thrombosis in femoral arteries and veins 
within 1 hour after application (Nemmar et al. 2002b). Interestingly, just nano-sized (60 
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nm) and not coarse (400 nm) polystyrene beads influenced thrombus formation, while 
both nano-sized and coarse polystyrene beads induced lung inflammation suggesting 
different mechanisms for these two processes (Nemmar et al. 2003b). Later, not just 
polystyrene beads but also DEP were shown to activate blood platelets and augment 
thrombus formation (Nemmar et al. 2003a). The prothrombotic effect of DEP was 
augmented even 6 and 24 hours after instillation and the instillation of DEP 
nanoparticles also induced an inflammatory reaction in the lung, i.e. increased 
granulocyte count and elevated histamine concentration in the bronchoalveolar lavage. 
Interestingly, H1 histamine receptor antagonist inhibited the increase in granulocyte 
counts in the bronchoalveolar lavage and the late (6- and 24-hour) prothrombotic 
effects, but did not affect the acute (1 hour) DEP-induced thrombosis or platelet 
activation (Nemmar et al. 2003c). These findings suggest that both mechanisms 
contribute to the prothrombotic effect of DEP nanoparticles: translocated nanoparticles 
induce early prothrombotic effects by direct activation, while lung inflammatory 
mediators generate late prothrombotic effects.  
The above investigations evoked further studies to find out how the interaction of 
ultrafine particles with blood can influence haemostasis. Several experiments 
demonstrated the role of platelet activation in the prothrombotic effects of ultrafine 
particles. In vitro experiments found increased P-selectin expression, augmented platelet 
aggregation, and the formation of platelet-leukocyte aggregates upon the incubation of 
blood with ultrafine particles (Nemmar et al. 2002b, Nemmar et al. 2003a, Nemmar et 
al. 2003b, Nemmar et al. 2003c, Radomski et al. 2005, Khandoga et al. 2010, Nemmar 
et al. 2010, Forestier et al. 2012, Kim et al. 2012). Using in vivo microscopy, platelet 
accumulation was found in the hepatic microcirculation in mice upon injection of 
carbon black ultrafine particles. Platelet adhesion to endothelial cells was strongly 
associated with fibrin deposition, and the blockade of the fibrinogen receptor αIIbβ3 
inhibited platelet accumulation in the liver (Khandoga et al. 2004). In the recent work of 
our research group (Khandoga et al. 2010), a similar experiment was carried out, but 
instead of systemic injection, inhalative exposure was used for the application of carbon 
black nanoparticles. The experiment showed the same result: platelets accumulated in 
the microcirculation of the liver. Fibrin deposition was found on the endothelial surfaces 
of the microcirculation in the liver and heart. In contrast, according to data obtained 
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from the bronchoalveolar lavage, a significant pulmonary inflammatory response did 
not occur and neither the plasma levels of proinflammatory cytokines nor blood cell 
counts were affected. These data suggest that inhaled carbon black nanoparticles 
generate prothrombotic effects, also without inducing an inflammatory response in the 
lungs.  
These data were further confirmed by controlled human exposure experiments. 
Inhalation of elemental carbon ultrafine particles by patients with type 2 diabetes 
mellitus for 2 hours increased the CD40 ligand expression of platelets and the number 
of platelet-leukocyte aggregates (Stewart et al. 2010). In the experiment of Lucking et 
al. healthy volunteers were exposed to DEP, and thrombus formation was measured in a 
Badimon ex vivo perfusion chamber. The Badimon chamber consists of a pump to draw 
blood from the cubital vein through a perfusion chamber with a strip of porcine aorta. 
Diesel exhaust particles increased thrombus formation and the formation of platelet-
leukocyte aggregates (Lucking et al. 2008). 
Ambient nanoparticles were also found to activate the coagulation system (Nemmar 
et al. 2010, Kilinc et al. 2011). The authors concluded that early procoagulant effects are 
dependent on the TF-driven extrinsic pathway, whereas long-lasting thrombogenic 
actions are due to translocated ultrafine particles inducing contact-dependent activation 
of the coagulation cascade (Kilinc et al. 2011). 
Summarising the experimental data about prothrombotic mechanisms of inhaled 
particulate matter suggests that larger ambient particles deposit in the lung and induce 
procoagulative changes through inflammatory mediators, whereas nano-sized ambient 
particles immediately translocate in the circulation, directly activate platelets, and later 
on activate the coagulation system via contact activation. 
 
d) Manufactured nanoparticles and thrombus formation  
The research performed on biomaterials and particulate matter indicates that 
manufactured nanoparticles might also influence thrombus formation. In spite of the 
fact that manufactured nanoparticles are produced in high amounts, their effects on the 
thrombotic process have been investigated to a lesser extent.  
Most information concerning the prothrombotic effects of nanoparticles have been 
obtained from in vitro experiments. Increased platelet activation and aggregation were 
DOI:10.14753/SE.2016.1824
 36 
found to be induced by amine-modified polystyrene beads (Nemmar et al. 2002b, 
Mayer et al. 2009, McGuinnes et al. 2011), quantum dots (Geys et al. 2008), titanium 
dioxide nanorods (Nemmar et al. 2008), and gold nanoparticles (Deb et al. 2011). 
However, in another study gold nanoparticles failed to affect platelet function or 
coagulation (Dobrovolskaia et al. 2009). Silver nanoparticles were found to prevent 
platelet activation, adhesion, and aggregation in a concentration-dependent manner, and 
to inhibit fibrin polymerisation (Shrivastava et al. 2009, Shrivastava et al. 2011). 
Coagulation was induced by synthetic amorphous silica and organically modified silica 
nanoparticles (Tavano et al. 2010), polylactic acid nanoparticles (Sahli et al. 1997), and 
titanium dioxide nanotubes, whereas titanium dioxide nanoparticles inhibited the 
coagulation system (Roy et al. 2007). Nano-sized copper (II) oxide caused up-regulation 
of plasminogen activator inhibitor-1 in endothelial cells (Yu et al. 2010).  
There is much less data about the effect of nanoparticles on thrombus formation in 
vivo. It has been shown that amine-modified polystyrene nanoparticles augmented and 
carboxyl-modified polystyrene nanoparticles inhibited thrombus formation in femoral 
vessels (Nemmar et al. 2002b). Carbon nanotubes were found to augment ferric 
chloride-induced thrombosis in vivo (Radomski et al. 2005). TiO2 rutile nanorods 
decreased the platelet count in vivo (Nemmar et al. 2008). Intravenous administration of 
quantum dots (Geys et al. 2008) or mesoporous silicate nanoparticles (Hudson et al. 
2008) were shown to induce pulmonary thrombosis.  
The above studies have investigated thrombus formation in large vessels. Although 
nanoparticles also reach the microcirculation, there are only a few recent publications 
that have analysed the effects of nanoparticles on thrombus formation in the 
microvasculature. Amine-modified polystyrene nanoparticles as benchmark particles 
were shown to induce a dose-dependent enhancement of thrombus formation in the 
microcirculation (Silva et al. 2005). Additionally, a previous study from our research 
group has demonstrated that systematically administered carbon black nanoparticles 
enhanced platelet accumulation on the endothelium of postsinusoidal venules and 
sinusoids in the hepatic microcirculation (Khandoga et al. 2004). However, the effects 
of manufactured nanoparticles on thrombus formation in the microcirculation have not 
been investigated yet.  
DOI:10.14753/SE.2016.1824
 37 
III. Aims 
The main objective of my research work was to investigate platelet activating and 
microcirculatory prothrombotic effects of manufactured nanoparticles.  To achieve these 
aims, some methodological problems also had to be solved, i.e. the preparation of 
nanoparticle dispersions in physiological solutions and the optimisation of the platelet-
granulocyte complex measurement.  
 
1. Optimisation of the preparation method of nanoparticle dispersions  
For investigations of in vitro and in vivo prothrombotic effects, nanoparticles have to be 
dispersed in physiological solutions. However, nanoparticles in solutions with 
physiological salt concentrations and pH values form coarse agglomerates. To avoid the 
formation of coarse agglomerates, a steric stabiliser has to be added to the nanoparticle 
dispersions. To optimise the dispersion method, we varied the following factors while 
preparing the nanoparticle dispersions: 
i) ultrasound energy levels 
ii) type of dispersion stabilizer: human, bovine, or mouse albumin, Tween 80, 
or mouse serum 
iii) concentration of dispersion stabilizer 
iv) concentration of nanoparticles 
v) sequence of preparation steps 
vi) stability of the dispersion over time 
vii) We also tested our method on a broad range of various types of 
nanoparticles. 
 
2. Optimisation of platelet-granulocyte complex measurement 
For the evaluation of platelet activation, also the amount of platelet-granulocyte 
complexes was measured. The measurement of platelet-granulocyte complexes with a 
flow cytometer is based on the simultaneous detection of fluorescent signals from both 
cell types. However, these double-positive signals can also originate from the 
coincidence of non-interacting platelets and granulocytes in the detection volume. Our 
aim was to develop a method that measures the real amount of platelet-granulocyte 
complexes without overestimating it due to coincidence.  
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3. Prothrombotic effects of nanoparticles 
Ambient nanoparticles have been shown to exert prothrombotic effects, but 
manufactured nanoparticles are less well investigated in this regard. Although 
circulating nanoparticles also reach the microcirculation, the effects of manufactured 
nanoparticles on microcirculatory thrombus formation have not been investigated yet. 
Thus the aim of this study was: 
i) to characterize the effects of DEP, titanium dioxide rutile, and single-walled 
carbon nanotube nanoparticles on platelet activation and 
ii) on the formation of platelet-granulocyte complexes in vitro 
iii) to assess their impact on thrombus formation in small arteries and in the 
microcirculation in vivo, and 
iv) to compare these effects with those induced by surface-modified polystyrene 
beads as benchmark particles. 
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IV. Materials and Methods 
 
1. Materials 
 
a) Nanoparticles 
 
Table 3. Nanoparticles used in our study, name of company, and size of nanoparticles 
as given by the manufacturer. 
Nanoparticle Size Company 
Titanium(IV) oxide 
nanopowder 99.5% rutile 
~10 nm × 40 nm Sigma-Aldrich, Schnelldorf, 
Germany 
Titanium(IV) oxide 
nanopowder 99.7% 
anatase 
<25 nm Sigma-Aldrich, Schnelldorf, 
Germany 
Zinc oxide nanopowder <100 nm Sigma-Aldrich, Schnelldorf, 
Germany 
Plain polystyrene beads 60 nm Bangs Laboratories, Fishers, 
USA 
Carboxyl-modified 
polystyrene beads 
60 nm Bangs Laboratories, Fishers, 
USA 
Amine-modified 
polystyrene beads 
65 nm Bangs Laboratories, Fishers, 
USA 
S-purified SWNT  outer diameter < 2 
nm, length 1–5 μm 
SES research, Houston, USA 
S-purified MWNT  outer diameter 10–30 
nm, lengths 1–2 μm 
SES research, Houston, USA 
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Nanoparticle Size Company 
DEP - SRM 2975  no data National Institute of Standards 
and Technology, Gaithersburg, 
USA 
Silicon oxide 99.5% 10 nm Nanostructured and Amorphous 
Materials Inc, Los Alamos, USA 
Silver synthesized 99.5% 30–50 nm Nanostructured and Amorphous 
Materials Inc, Los Alamos, USA 
 
b) Reagents 
Mouse serum albumin (MSA), bovine serum albumin (BSA), 10 × concentrated 
phosphate buffered saline (PBS), and 10 × concentrated RPMI 1640 medium, 
fluorescein isothiocyanate (FITC) dextran 150 kD, epinephrine-bitartrate, ADP, 
ethylenediaminetetraacetic acid (EDTA), and lipopolysaccharide (LPS) from 
Escherichia Coli O111:B4 were purchased from Sigma-Aldrich, Schnelldorf, Germany. 
Human serum albumin (HSA) 50 g/l was from Baxter Deutschland Gmbh, Heidelberg, 
Germany. BSA-Tyr buffer contained: 0.35% BSA, 10 mM Hepes, 137 mM NaCl, 2.8 
mM KCl, 1 mM MgCl2, 12 mM NaHCO3, 0.4 mM Na2HPO4, 5.5 mM glucose, pH 7.4. 
 
c) Mouse serum 
C57BL/6NCrl male mice (Charles River, Sulzfeld, Germany) were anaesthetised with 
isoflurane-N2O (FiO2 0.35, 0.015 l/l isoflurane; Forene; Abbott GmbH, Wiesbaden, 
Germany). Blood was taken by heart puncture and allowed to clot. The blood was 
centrifuged at 1400 g for 20 minutes and the supernatant was taken. Serum samples 
were pooled and aliquots were stored at -20°C until use. 
 
d) Antibodies and fluorescent beads for flow cytometry 
For the flow cytometric detection of platelets, PE-labelled anti-CD62P (Dako, Glostrup, 
Denmark), FITC-labelled anti-CD41 (Immunotech, Marseilles, France), and mouse 
IgG1-FITC isotype control (DAKO, Denmark, Glostrup) as well as for detection of 
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granulocytes PC5-labelled anti-CD15 (Immunotech, Marseilles, France) antibodies 
were used. For modelling coincidence, FL1 fluorescent FITC (Calibrite, Becton 
Dickinson, USA) and FL3 fluorescent Starfire Red™ labelled (QuantumPlex, Level IV, 
Bangs Laboratories, USA) beads were applied. 
 
2. Characterisation of nanoparticles 
The characterisation of nanoparticle dispersions involved the measurement of size 
distribution and zeta potential, visualisation with transmission electron microscopy, and 
determination of the endotoxin content.  
 
a) Size distribution and zeta potential measurement  
The size distribution and the zeta potential of nanoparticles were analysed in aqueous 
dispersion with a Zetasizer Nano ZS instrument (Malvern, Malvern Hills, United 
Kingdom). 
Dynamic light scattering is used by the instrument to determine the size distribution 
of particles by measuring dynamic fluctuations of the scattered light intensity due to the 
Brownian motion of the particles. 
This technique yields the Z-average hydrodynamic diameter of the particles 
calculated from the peak values of the hydrodynamic diameter distribution via the 
Stokes-Einstein equation. This type of measurement also provides the polydispersity 
index (PdI) that describes the width of the particle size distribution. The PdI scale 
ranges from 0 to 1, where a higher number means higher polydispersity. Each assigned 
size and PdI value was the mean of 10 runs. All measurements were carried out in 
triplicate with a temperature equilibration time of 1 minute at 25°C. The following 
parameters were used in the instrument settings to allow for a correct optical model: The 
refractive index values of the nanoparticles were taken from the literature. For the 
dispersant, a refractive index of 1.330 and a viscosity of 0.8872 cP were chosen. The 
data processing mode was set to high multi-modal resolution. 
The measurement technique used by the Zetasizer Nano ZS to measure the zeta- 
potential of particles in a solution is known as phase analysis light scattering. This 
technique uses a laser which is passed through the sample to measure the velocity of the 
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particles in an applied electric field of known value. Among other factors, velocity 
depends on the zeta potential of the nanoparticles. The optical model for zeta potential 
measurements was interpreted using Smoluchowski’s method, since the particles were 
dispersed in polar solvents. 
For measuring the accuracy of size and zeta potential measurement, 60 nm plain 
carboxyl- and amine-modified particles were prepared at a concentration of 0.02 mg/ml 
in distilled water. 
 
b) Transmission electron microscopy 
Nanoparticles were visualised with a transmission electron microscope (Jeol JEM 2010) 
operated at 200 kV. Samples for transmission electron microscopy were prepared by 
letting a drop of nanoparticle dispersion dry onto a perforated carbon layer-covered 
copper mesh grid (Agar Scientific Ltd., Stansted, UK). The mean particle size in the 
TiO2 (rutile) dispersions prepared with HSA was analysed by measuring the diameter of 
100 particles using Image J software (National Institutes of Health, Bethesda, USA). 
 
c) Endotoxin measurement  
Nanoparticle dispersions prepared by the above method were tested with the LAL 
(Limulus amoebocyte lysate) kinetic chromogenic assay (Lonza, Verviers, Belgium). 
The endotoxin content in DEP, TiO2 (rutile), and SWNT dispersions was below 0.5 
EU/ml. 
 
3.  Optimisation of the nanoparticle dispersion method 
For in vitro and in vivo studies, a new dispersion method was needed to avoid formation 
of nanoparticle agglomerates in physiological solutions. The preparation had to be 
optimised. The optimal conditions for each preparation step and the best preparation 
sequence were tested in terms of their effect on the agglomeration state of nanoparticle 
dispersions. The agglomeration state of aqueous dispersions was analysed with dynamic 
light scattering and transmission electron microscopy (see above). The following factors 
were tested and optimised: 
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a) Effect of different ultrasound energies 
A TiO2 (rutile) stock solution was prepared at a concentration of 0.02 mg/ml in distilled 
water. One ml of the nanoparticle dispersion was sonicated with a Hilscher UP50H 50 
watt, 30 kHz sonicator (Hilscher Ultrasonics GmbH, Teltow, Germany) using different 
intensities (20%, 50% or 100%) and different time intervals (10 sec, 1 min or 5 min). 
The power consumption of the sonicator was measured with a power-measuring device 
during sonication of the particles (working operation) and during sonication of air (no-
load operation). The specific energy was calculated as: Espec= (Pwork-Pno-load) × t/V, 
where Pwork and Pno-load are the power consumptions of working and no-load operations, 
t is the duration of the sonication, and V is the volume of the dispersion (Hilscher 
2005). 
 
b) Various sequences of preparation steps 
To evaluate the effect of various sequences of preparation steps, a TiO2 (rutile) stock 
solution was prepared at a concentration of 0.02 mg/ml in distilled water with or 
without sonication with 4.2 × 105 kJ/m3 specific energy. Thirty μl of HSA (end 
concentration 1.5 mg/ml) or Tween 80 (end concentration 0.1%) was given to 870 μl of 
dispersion before or after the addition of 100 μl of a 10 × concentrated PBS solution. 
 
c) Mediums and dispersion stabilisers  
The TiO2 (rutile) dispersion was also prepared in a similar way using RPMI 1640 cell 
culture medium and with the addition of other dispersion stabilisers, i.e. 1.5 mg/ml 
MSA, 1.5 mg/ml BSA, 0.1% Tween 80, or 30 μl mouse serum. 
The effect of different TiO2 rutile (0.002, 0.02, 0.2, 2 mg/ml) and HSA (0.0015, 
0.015, 0.15, 1.5, and 15 mg/ml) concentrations was tested.  
 
d) Different types of nanoparticles 
Dispersions were also prepared from TiO2 (anatase), ZnO, SWNT, MWNT, silver, 
SiOx, and SRM 2975 DEP by preparing 0.02 mg/ml stock solutions, sonicating with 
4.2 × 105 kJ/m3 specific ultrasound energy, adding 1.5 mg/ml HSA, 0.1% Tween, or 
30 μl serum prior to the addition of concentrated PBS. 
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e) Evaluation of the stability of nanoparticle dispersions 
The stability of 0.02 mg/ml TiO2 (rutile) dispersions prepared by sonication with 
4.2 × 105 kJ/m3 energy and by the addition of 1.5 mg/ml HSA followed by PBS was 
measured for 1 week.  
 
4. Dispersion of nanoparticles 
Based on the previous optimisation, the following dispersion method was used for in 
vitro and in vivo experiments. DEP, TiO2 (rutile), or SWNT stock solutions were 
prepared at a concentration of 0.23 mg/ml in distilled water using sonication with 
4.2 × 105 kJ/m3 specific energy. For in vitro experiments with human blood, 30 μl of 
50 mg/ml human serum albumin (end concentration 1.5 mg/ml) and for in vivo mouse 
experiments 30 µl of mouse serum was given to 870 μl of dispersion before the addition 
of 100 μl of a 10× concentrated PBS solution. To  prepare dispersions at lower 
concentrations, dilutions of the stock solution were used. The end concentrations of 
nanoparticles in the dispersion were 0.002, 0.02 and 0.2 mg/ml. The vehicle was 
prepared in the same way, but instead of nanoparticle dispersion, 870 µl of distilled 
water was added to human serum albumin or mouse serum and to concentrated PBS. 
Dispersions with amine- and carboxyl-modified polystyrene nanoparticles were 
prepared in PBS at 0.2 mg/ml without sonication or addition of human serum albumin 
or mouse serum.  
 
5. Blood collection for in vitro studies 
For flow cytometric and aggregometry measurements, blood was collected from the 
cubital vein of healthy volunteers into citrate anticoagulant-containing Vacuette 
(Greiner, Austria, Kremsmünster) test tubes. In some cases, when platelet–granulocyte 
coincidence was modelled, EDTA was used as anticoagulant. All samples were 
obtained with the approval of the local Ethical Committee after the donor had given 
informed consent.  
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6. Optimisation of the platelet-granulocyte complex 
measurement 
 
a) Experimental analysis of coincidence 
Measurement of fluorescent beads 
To model platelet–granulocyte coincidence experimentally, FL1 fluorescent and FL3 
fluorescent beads were mixed at 225,000/μl and 5000/μl final concentrations 
respectively, corresponding to the platelet and granulocyte concentrations in the blood. 
Bead mixtures were measured in the flow cytometer after 10–320-fold dilutions with 
PBS (n=4). 
 
Measurement in EDTA anticoagulated blood 
To measure coincidence of platelets and granulocytes in the flow cytometer, EDTA 
anticoagulated blood samples (n=7) were stained by fluorescent-labelled antibodies: 20 
μl anti-CD15-PC5 as a granulocyte marker and 10 μl anti-CD41-FITC as a platelet 
marker were added to 100 μl of blood. The non-specific binding of antibodies was 
measured using appropriate isotype controls. The samples were incubated for 30 min in 
the dark at room temperature. After incubation, samples were diluted with 2 mM Na2-
EDTA containing PBS. The final blood dilutions were 6.625-, 20-, 40-, 80-, 160- and 
320-fold. To minimize platelet activation, no washing or vortexing procedures were 
used (Hagberg and Lyberg 2000). 
 
Measurement in citrate anticoagulated blood 
To measure platelet–granulocyte complexes, citrated blood samples (n=9) were kept at 
room temperature for 30 ± 10 min to ensure in vitro complex formation (Li et al. 1999, 
Peters et al. 1999, Hagberg and Lyberg 2000) and stained in the same way as the EDTA 
anticoagulated blood samples. Then, 130 μl of stained sample was made up to 1 ml with 
PBS containing 1% paraformaldehyde and 0.38% Na3-citrate (final dilution of blood: 
10-fold) and kept at room temperature for 1 h to stabilize the in vitro formed complexes. 
These samples were further diluted with PBS containing 1% paraformaldehyde and 
0.38% Na3-citrate, as in the case of the EDTA samples. The final blood dilutions were 
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6.625-, 20-, 40-, 80-, 160- and 320-fold. No washing or vortexing procedures were 
used. 
 
Detection of platelet-granulocyte complexes using fluorescent beads 
To determine the extent of coincidence in the presence of real complexes, citrated blood 
samples were stained only for CD 41, fixed and diluted as above. Right before flow 
cytometric measurement 10 μl (~107/ ml) of FL3 fluorescent beads were mixed into 500 
μl of fixed diluted citrated blood samples to ensure a bead concentration comparable to 
that of granulocytes. 
 
Flow Cytometry 
Samples were run on a Becton Dickinson FACScan flow cytometer at high (1 μl/s) flow 
rate and at 488 nm excitation wavelength. Data acquisition was triggered by the FL3 
signals detected at 650 nm. To ensure that granulocytes or fluorescent beads triggered 
the data collection, the appropriate threshold was determined in separate measurements 
based on the FL3 histogram and on the light scattering profile. 5000 events were 
collected in every measurement. The FL1 positive events (CD41+ platelets or FITC 
labelled beads, detected at 530 nm) were evaluated as a percentage of FL3 positive ones 
(Fig. 11).  
 
Fig. 11. Representative dot plot of an EDTA anticoagulated blood sample at 40-fold 
dilution. Only CD15 positive data were acquired. The ratio of double (CD15+ and 
CD41+) positive events is 14.8%. (Bihari et al. 2008a) 
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Cell Counts 
Granulocyte and platelet counts were determined in undiluted blood samples by 
standard procedures on an Abbott Celldyn 3500 haematological analyser. 
 
b) Mathematical description of coincidence 
The phenomenon of coincidence occurring during the sorting of cells at high-speed by a 
flow cytometer has been discussed by Keij et al. (Keij et al. 1991). Instead of the time 
bins used by them, it seemed more practical to introduce the detection volume as a way 
to describe coincidence of platelets and granulocytes (Fent et al. 2008). The detection 
volume is that fraction of the sample volume in which fluorescent signal collection 
occurs during the detection of one event (Fig 12.). 
 
 
Fig. 12. Principle of flow cytometric measurement of platelet-granulocyte complexes. 
Real platelet-granulocyte complexes are undistinguishable from separated platelets and 
granulocytes that coincide in the detection volume. The detection volume is given by 
multiplication of the volume flow rate of the cell suspension and the time duration of the 
detection. Slightly modified after Fent et al. (Fent et al. 2008). 
 
The easiest way to describe coincidence mathematically, in a complex system where 
a different number of platelets can adhere to or can coincide with a granulocyte in the 
detection volume, is to determine the probability of the complementary event, i.e. the 
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probability that triggering originates from a platelet marker negative granulocyte (pn). 
The probability pn can be given as the product of two probabilities:  
(1) cn ppp 0=  
p0 denotes the probability that no free platelets are in the detection volume and pc is the 
probability that the triggering event originates from a single granulocyte and not from a 
platelet–granulocyte complex. 
(2) [ ][ ]G
C1−=cp  
where [G] and [C] represent the concentration of granulocytes and complexes in the 
blood sample respectively. The probability that a given number of platelets occurs in the 
detection volume (Vd) can be calculated from the Poisson distribution. Poisson 
distribution describes the probability (pk) of a given number of events (k) occurring 
within a time or space (e.g. volume) interval, when a single event occurs with a steady 
probability (p). For calculation purposes, platelets and granulocytes are considered 
point-like particles without dimension, where n is the number of platelets given in the 
examined blood. 
 
(3)  ( ) np
k
k ek
npp −=
!
 
 
When no free platelets are in the detection volume, k=0 and the probability (p0) can be 
calculated as follows: 
(4) ( ) npnp eenpp −− ==
!0
0
0  
where n, the number of platelets in the volume of blood examined (Vall) can be 
calculated from the platelet concentration ([T]): 
(5) [ ]TallVn =  
and p is the probability of platelet–granulocyte coincidence if only one platelet was to 
be found in Vall 
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(6) 
all
d
V
Vp =  
From Eqs. (4), (5) and (6) one gets:  
(7) [ ] dVT-0 eep
np == −  
Combining Eqs. (1), (2) and (7): 
(8) [ ] [ ][ ]




−+−=
G
CVp dn 1ln   Tln  
If “D” means the percentage of platelet marker positive events in the granulocyte gate, 
pn can be estimated from the flow cytometric measurements in the following way: 
(9) 100/1 Dpn −=  
and thus plotting 
(10) ( )100/1ln DY −=  
as a function of platelet concentrations results in a straight line if [C]/[G] and Vd are 
independent of [T] (Eq. (8)). [C]/[G] independence of [T] means that the sample 
contains only dilution-resistant complexes. Vd independence of [T] means that the 
velocity of cell suspension or the duration of event detection does not change depending 
on the event count. The intercept of that straight line contains information on the 
amount of dilution resistant stable complexes. The negative slope of the straight line 
equals the detection volume. 
 
7. Measurement of platelet activation in vitro 
 
a) Incubation of whole blood with nanoparticles 
Platelet activation and formation of platelet-granulocyte complexes in the presence of 
nanoparticles in human whole blood was determined by flow cytometry. 100 μl of 
citrated blood was incubated with 100 µl of vehicle or 100 μl of nanoparticle dispersion 
for 10 minutes at room temperature. Dispersions of amine-, carboxyl-modified 
polystyrene bead, DEP, and TiO2 (rutile) nanoparticles had a concentration of 0.2 
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mg/ml and SWNT dispersions had concentrations of 0.002, 0.02 or 0.2 mg/ml. After 
incubation, samples were diluted 5-fold with BSA-Tyr buffer. As a positive control, 
blood samples diluted 10 times with BSA-Tyr buffer were incubated with 1 μM ADP 
(final concentration) for 10 minutes.  
 
b) Flow cytometry 
Measurement of platelet P-selectin 
Samples were stained with PE-labelled anti-CD62P antibodies and FITC-labelled anti-
CD41 antibodies according to the manufacturer’s instructions. To check non-specific 
binding of the antibodies, appropriate isotype control antibodies were used. After 
staining, samples were diluted 50-fold with BSA-Tyr buffer (500-fold final dilution of 
blood). To minimize the spontaneous activation of platelets, no washing steps were 
used. Samples were run on a Becton Dickinson FACScan flow cytometer. 5000 events 
were collected in every measurement. The CD41 platelet marker was used as a trigger 
signal for data collection. Platelets were gated on the FS-SS dot plot, and the mean 
CD62P fluorescence intensity was analysed for CD41 positive events.  
 
Measurement of platelet-granulocyte complexes 
For the measurement of platelet-granulocyte complexes, the previously optimised flow 
cytometric method with high sample dilution was used (see results and discussion of the 
optimisation below in section V/2 and VI/2). Samples were stained according to the 
manufacturer’s instructions with FITC-labelled anti-CD41 and PC5-labelled anti-CD15 
antibodies. To check the non-specific binding of the antibodies, appropriate isotype 
control antibodies were used. After staining, samples were diluted 50-fold with BSA-
Tyr buffer (500-fold final dilution of blood). To minimize the spontaneous activation of 
platelets, no washing steps were used. Samples were run on a Becton Dickinson 
FACScan flow cytometer. 5000 events were collected in every measurement. Platelet-
granulocyte complexes were detected as double-positive events in the granulocyte gate. 
Here, the CD15-PC5 granulocyte marker was used as a trigger signal. The amount of 
platelet-granulocyte complexes was determined as a percentage of CD41 positivity in 
the CD15-positive gate.  
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c) Aggregometry 
In vitro aggregation of human platelets in the presence of nanoparticles was detected 
with a Chronolog Whole Blood Lumi-Aggregometer type 560 C (Chrono-Log, 
Havertown, USA) by measuring the optical density in plastic cuvettes at 37 oC with 
continuous stirring (1000 RPM). The reaction mixture contained 400 μl of platelet-rich 
plasma (PRP) and 100 μl of 0.5 mg/ml nanoparticles. Platelet-poor plasma (PPP) 
containing the same amount of nanoparticles served as reference. After running samples 
for at least 10 minutes, 1 μM of ADP was added to check the aggregation ability of 
platelets. Data were collected with both a two-channel recorder and a computer. 
Aggregation in the presence of nanoparticles is given as a percentage of that induced by 
ADP. 
 
8. Detection of in vivo thrombus formation  
 
a) Animals  
C57BL/6NCrl mice were purchased from Charles River (Sulzfeld, Germany). All 
experiments were performed with male mice with a body weight of 15 to 22 g (18.6 ± 
1.6 g) for mesenteric thrombosis and 20 to 27 g (24.0 ± 1.5 g) for cremasteric 
thrombosis experiments. Animals were raised in a specific pathogen-free environment 
and later housed under conventional conditions with free access to food and water. All 
experiments were performed according to the German legislation for the protection of 
animals. 
 
b) Ferric chloride-induced thrombosis in small mesenteric arteries  
Surgical procedure  
Mice were anaesthetised using a ketamine (100 mg/kg) / xylazine (10 mg/kg) mixture 
administered by intraperitoneal injection. The carotid artery was cannulated in a 
retrograde manner for the administration of FITC-dextran, nanoparticles, or vehicle. For 
intravital microscopy, the mesentery was exteriorized gently through a midline 
abdominal incision. At the end of the experiment blood was collected from the heart and 
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blood cell counts were measured with a Coulter Ac T 8 haematology analyser 
(Beckman Coulter, Fullerton, USA). 
 
Intravital microscopy 
The set-up for intravital microscopy was centred around a Zeiss Axiotech upright 
microscope, equipped for fluorescence epi-illumination microscopy. Light from a 100-
W HBO source was directed onto the specimen via a FITC filter cube (Ex 450-490, FT 
510, LP 520). Microscopic images were obtained with Epiplan lenses (10x / NA 0.2) 
and recorded with a black and white CCD video camera (FK 6990A-IQ, Pieper, 
Schwerte, Germany) and a digital video recorder (Sony DSR-45P DVCAM). 
 
Experimental protocol 
The experiments were performed as described earlier (Andre et al. 2003) with minor 
modifications. After surgical preparation, either DEP, TiO2 (rutile), SWNT 
nanoparticles at a concentration of 1 mg/kg (in a volume of 5 µL/g body weight), 
polystyrene nanoparticles at a concentration of 0.5 mg/kg body weight (in a volume of 
2.5 µL/g body weight), vehicle, or physiological saline were injected through the 
catheter into the mice 10 minutes prior to induction of thrombosis in order to yield a 
uniform distribution of the particles in the microcirculation. One small mesenteric artery 
(diameters 140-230 µm) per animal was recorded. Vessel wall injury was generated at 
10 minutes after nanoparticle application by placing a 1 x 2 mm filter paper saturated 
with a 5% FeCl3 solution over the artery for 7 minutes (Fig. 13). Cessation time was 
defined as time between induction of vessel wall injury and complete occlusion of the 
artery. In vessels without complete occlusion until the end of the recording, the 
cessation time was considered to be 40 min. As a positive control, mice were given 
epinephrine intra-arterially at a blood concentration of 12.5 µM (blood volume was 
estimated to be 2 ml) immediately prior to the induction of thrombosis. 
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Fig. 13. Ferric chloride-induced thrombosis in mesenteric arteries. The mesentery is 
exteriorized through a midline abdominal incision and thrombus formation is induced 
by placing a 1 x 2 mm filter paper saturated with a 5% FeCl3 solution over the artery 
(140-230 µm) for 7 minutes. 
 
c) Light/dye-induced thrombosis in the cremasteric microcirculation 
Surgical procedure 
Light/ dye-induced thrombosis in the cremaster microcirculation was carried out in a 
separate set of experiments. The surgical preparation of the cremaster muscle was 
performed as originally described by Baez (Baez 1973) with minor modifications.  Mice 
were anaesthetised using a ketamine (100 mg/kg) / xylazine (10 mg/kg) mixture 
administered by intraperitoneal injection. The left femoral artery was cannulated in a 
retrograde manner for the administration of FITC-dextran and nanoparticles or vehicle. 
The right cremaster muscle was exposed through a ventral incision of the scrotum. The 
muscle was opened ventrally in a relatively avascular zone, using careful electrocautery 
to stop any bleeding, and spread over the pedestal of a custom-made microscopic stage. 
Epididymis and testicle were detached from the cremaster muscle and placed into the 
abdominal cavity. Throughout the surgical procedure, the muscle was superfused with 
warm Ringer solution. At the end of each experiment, blood was collected from the 
heart for measurement of blood cell counts. 
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Intravital microscopy 
The set-up for intravital microscopy was centred around an Olympus BX 50 upright 
microscope (Olympus Microscopy, Hamburg, Germany). Light from a 75-W xenon 
source was narrowed to a near monochromatic beam of a wavelength of 488 nm by a 
galvanometric scanner (Polychrome II, TILL Photonics, Gräfelfing, Germany) and 
directed onto the specimen via a FITC filter cube equipped with dichroic and emission 
filters (DCLP 500, LP515, Olympus Microscopy). Microscopic images were obtained 
with Olympus water immersion lenses [20x /NA 0.5 and 60x/NA 0.9], recorded with a 
CCD camera (IMAGO S/N 382KLO345; TILL Photonics GmbH, Gräfelfing, Germany) 
and subjected to digital image analysis (TILLvisION 4.0; TILL Photonics GmbH, 
Gräfelfing, Germany).  
 
Experimental protocol 
Light/dye-induced thrombosis was performed as described earlier (Rumbaut et al. 2006) 
with slight modifications (Fig. 14). The light intensity was measured by a photodiode at 
488 nm at the exit of the light source daily and maintained to be between 2.65 and 2.75 
mA. After surgical preparation either polystyrene nanoparticles at a concentration of 0.5 
mg/kg body weight (in a volume of 2.5 µL/g body weight), or DEP or TiO2 (rutile) at a 
concentration of 1 mg/kg body weight (in a volume of 5 µL/g body weight), or SWNT 
at a concentration of 0.01, 0.1 and 1 mg/kg body weight (in a volume of 5 µL/g body 
weight) or vehicle or physiological saline (control) were injected through the catheter. 
The nanoparticles were administered 10 minutes prior to induction of thrombosis in 
order to yield a uniform distribution of the particles in the microcirculation. Thereafter, 
4 ml/kg body weight FITC-dextran (2.5%) was given. To verify comparable 
intravascular FITC concentrations among experimental groups, digital images were 
taken from one venule and the mean grey fluorescence intensity was measured. 
Ten minutes after the application of nanoparticles, photoactivation was induced by 
exposing a vessel segment of 300 µm length to continuous epi-illumination with a 
wavelength of 488 nm. An Olympus water immersion lens [60x / NA 0.9] was used to 
focus the light onto the cremaster and to obtain fluorescent images. Thrombus formation 
was quantified in one arteriole (25-35 µm) and one venule (30-50 µm) by analysing the 
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time when platelets became adherent to the vessel wall (onset) and the time required for 
complete occlusion of the vessel (cessation). The cessation time in vessels without 
complete occlusion until the end of the recording was considered 20 min for venules 
and 40 min for arterioles. As a positive control, mice were given 4 mg/kg body weight 
LPS intraperitoneally 4 hours prior to the induction of thrombosis. 
 
 
Fig. 14. Light/dye-induced thrombosis in cremasteric microvessels. The right cremaster 
muscle was exposed through a ventral incision of the scrotum and spread over the 
pedestal of a custom-made microscopic stage. Thrombus formation was induced in 
cremasteric microvessels (25-35 µm) by photoactivation of intravascular FITC-dextran 
molecules with 488 nm light. 
 
9. Statistics  
Data analysis was performed with a statistical software package (SigmaStat v3.0 for 
Windows, Jandel Scientific, Erkrath, Germany).  
For analysis of the data of the dispersion study, one way ANOVA followed by either 
the Dunnett (comparison versus control) or the Student-Newman-Keuls (all pairwise 
comparison) tests were used for the estimation of stochastic probability. The t-test was 
used to compare two groups.  
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Transformed flow cytometric data as a function of platelet concentration were fitted 
by the least squares method. Regression analysis was used to estimate the significance 
level of correlation coefficients and to judge the zero character of intercepts. 
ANOVA followed by Dunnett test (comparison versus control) for in vivo data and 
repeated measures ANOVA followed by Holm-Sidak test for human in vitro data was 
used for the estimation of stochastic probability. For the analysis of the aggregometry 
data, one-sample t-test was used. 
Data are given as mean values and standard error except the methodological studies, 
where mean values and standard deviation were used. P values < 0.05 were considered 
significant. 
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V.  Results 
 
1. Physical characterisation of nanoparticles and optimisation 
of the dispersion method 
Nanoparticles tend to form agglomerates in physiological solutions. Thus, for in vitro 
and in vivo studies where nanoparticles are in contact with physiological solutions, a 
new dispersion method for preparation of nanoparticles was necessary. To optimise the 
dispersion method, the effect of different factors on the agglomeration state of TiO2 
(rutile) nanoparticles was tested. Thereafter, using the optimal technique, other 
nanoparticles were prepared and physically characterised. 
 
a) Measurement of polystyrene beads 
First, the accuracy of size distribution and zeta potential measurements was verified by 
measuring 60–65-nm polystyrene beads with different surface charges in distilled water 
and also in PBS. The size measurements demonstrated almost identical results to those 
reported by the manufacturer. Amine-modified particles had positive while carboxyl 
and unmodified particles negative zeta potential (Tab. 4). 
 
Table 4. Size and zeta potential data of polystyrene beads. Polystyrene bead dispersions 
were prepared in distilled water (DI H2O) or in PBS at a concentration of 0.02 mg/ml 
without sonication. The measurements were made in triplicate. The average value (bold 
text) and the standard deviation (normal text) of the measurements are shown. (Bihari 
et al. 2008b) 
Particle 
Average 
Diameter 
(nm) PdI 
Zeta- 
Potential 
(mV) 
Electrophoretic 
Mobility 
(µmcm/Vs) 
Conductivity 
(mS/cm) 
Plain polystyrene beads (60 nm) 
DI H2O 67 0.030 -57.0 -4.466 0.009 
 0.4 0.004 5.3 0.412 0.010 
PBS 73 0.135 -24.8 -1.947 18.267 
 7 0.068 5.7 0.446 0.289 
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Particle 
Average 
Diameter 
(nm) PdI 
Zeta- 
Potential 
(mV) 
Electrophoretic 
Mobility 
(µmcm/Vs) 
Conductivity 
(mS/cm) 
Carboxyl-modified polystyrene beads (60 nm) 
DI H2O  60 0.046 -56.7 -4.443 0.003 
 0.3 0.021 0.3 0.021 0.000 
PBS 58 0.057 -32.5 -2.550 17.833 
 0.9 0.018 2.5 0.193 0.208 
Amine-modified polystyrene beads (65 nm) 
DI H2O 68 0.062 59.7 4.676 0.006 
 0.5 0.035 4.9 0.379 0.002 
PBS 86 0.204 19.0 1.493 18.100 
 8 0.029 3.4 0.268 0.100 
 
b) Ultrasound energy 
The effects of different ultrasound energies were tested on TiO2 (rutile) suspensions in 
distilled water. A specific ultrasound energy of 4.2 × 105 kJ/m3 (power consumption: 
7 W, 1 ml dispersion, 60 sec sonication) was sufficient to disaggregate TiO2 (rutile) 
nanoparticles as indicated by the reduction of the particle diameter from 527.6 ± 34.2 to 
159.7 ± 2.3 nm (Fig. 1) and of the PdI from 0.434 ± 0.086 to 0.166 ± 0.015 (data not 
shown). However, higher energy input did not further improve size reduction (Fig. 15). 
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Fig. 15. Effect of intensity of sonication on TiO2 (rutile) particle size. TiO2 (rutile) 
dispersed in distilled water at a concentration of 0.02 mg/ml was sonicated with 
different specific energies, and the average of the hydrodynamic diameter of the 
particles was measured. The experiments were carried out in triplicate (*, p < 0.05). 
(Bihari et al. 2008b) 
 
c) Sequence of preparation steps 
Various sequences of preparation steps of particle dispersions were assessed on TiO2 
(rutile) (Fig. 16). The average diameter and PdI of TiO2 (rutile) in PBS without 
sonication was 912 ± 48 nm and 0.509 ± 0.017, respectively. Addition of HSA or 
Tween 80 to the TiO2 (rutile) dispersion without previous sonication did not reduce the 
particle diameter in PBS. However, the TiO2 (rutile) particle diameter was reduced in 
PBS when HSA or Tween 80 was added to the dispersion after sonication. In the case of 
HSA, the diameter of TiO2 (rutile) particles was further reduced when the stabilizer was 
added prior to the addition of PBS. Best results were obtained with HSA as dispersion 
stabilizer when we first sonicated the TiO2 (rutile) nanoparticles in distilled water, then 
added the dispersion stabilizer, and at the end added buffered salt solution to the 
dispersion (average diameter = 186.4 ± 9.9 nm, PdI = 0.212 ± 0.03). In this case, the 
addition of HSA prior to the addition of PBS prevented the TiO2 (rutile) particles from 
reagglomeration (Fig. 17). Interestingly, the diameter of TiO2 (rutile) particles was 
slightly but significantly elevated after HSA addition (from 159.7 ± 2.3 to 174.2 ± 2.2, 
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Fig. 3). This dispersion protocol also worked well when RPMI 1640 cell culture 
medium was used as a dispersion medium. Similar results were obtained using BSA, 
MSA, or mouse serum as dispersion stabilizers (Fig. 18). 
 
 
Fig. 16. Role of the sequence of preparation steps. TiO2 (rutile) dispersed in distilled 
water at a concentration of 0.02 mg/ml was sonicated with 4.2 × 105 kJ/m3 specific 
energy (US) or not sonicated (no US). Tween 80 0.1% (T), HSA 1.5 mg/ml (A) or 
distilled water (W) was given to the dispersion before or after the addition of 
concentrated PBS. The average hydrodynamic diameter of the particles was measured 
(n = 4; *, p < 0.05 vs. dispersion in distilled water (W) without sonication (no US), 
#, p < 0.05 vs. dispersion in distilled water (W) with sonication (US), § p < 0.05). 
Slightly modified after Bihari et al. (Bihari et al. 2008b) 
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Fig. 17. Size distribution by volume of a TiO2 (rutile) dispersion measured after each 
preparation step. TiO2 (rutile) was dispersed in distilled water and sonicated (red), then 
HSA (blue) and finally concentrated PBS (green) was given to the dispersion. TiO2 
(rutile) was also prepared in the same way but without HSA (black). (Bihari et al. 
2008b) 
 
 
Fig. 18. Albumin from different species and serum as dispersion stabilizer. TiO2 (rutile) 
dispersed in distilled water at a concentration of 0.02 mg/ml was sonicated, and HSA, 
MSA, BSA or mouse serum was given to the dispersion before the addition of 
concentrated PBS. The average hydrodynamic diameter of the particles was measured. 
The experiments were carried out in triplicate (*, p < 0.05 vs. dispersion without 
albumin in PBS; #, p < 0.05 vs. dispersion without albumin or serum in RPMI). (Bihari 
et al. 2008b) 
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d) Albumin and nanoparticle concentration 
To optimize the HSA concentration for stabilization of dispersions, we prepared 
dispersions with different HSA or TiO2 (rutile) concentrations. When changing HSA 
concentration at a constant (0.02 mg/ml) TiO2 (rutile) concentration, we found that an 
HSA concentration between 0.015 mg/ml and 15 mg/ml prevented the formation of 
coarse TiO2 (rutile) agglomerates. However, at 0.0015 mg/ml HSA concentration, the 
average diameter and the PdI value of TiO2 (rutile) were increased (Fig. 19, 20). At an 
HSA concentration of 15 mg/ml, the average diameter of TiO2 (rutile) particles was 
slightly decreased. This decrease is not the result of a real change in the TiO2 (rutile) 
particle size, but the consequence of the presence of particles with a diameter of 7.1 ± 
0.1 nm (data not shown) in the dispersion. The presence of these particles, 
corresponding to free HSA molecules, causes a shift in the average diameter. The 
presence of the two types of particles with different diameters (TiO2 (rutile) and free 
HSA molecules) in the dispersion is also reflected in the strong increase of the PdI. 
 
 
Fig. 19. TiO2 (rutile) particle size in dispersions with different HSA concentrations. 
TiO2 (rutile) dispersed in distilled water at a concentration of 0.02 mg/ml was sonicated 
and HSA at concentrations ranging from 0.0015 to 15 mg/ml was given to the 
dispersion prior to addition of concentrated PBS. The average hydrodynamic diameter 
of the particles was measured. The experiments were carried out in triplicate 
(*, p < 0.05 vs. dispersion with 0.0015 mg/ml HSA). (Bihari et al. 2008b) 
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Fig. 20. Polydispersity index of TiO2 (rutile) in dispersions with different HSA 
concentrations. TiO2 (rutile) dispersed in distilled water at a concentration of 
0.02 mg/ml was sonicated and HSA at concentrations ranging from 0.0015 to 15 mg/ml 
were given to the dispersion prior to addition of concentrated PBS. Polydispersity index 
(PdI) of the particles was measured. The experiments were carried out in triplicate 
(*, p < 0.05 vs. dispersion with 0.0015 mg/ml HSA). (Bihari et al. 2008b) 
 
Next, we prepared dispersions with different TiO2 (rutile) concentrations, but the same 
HSA (1.5 mg/ml) concentration. We found that HSA prevented the formation of coarse 
agglomerates at TiO2 (rutile) concentrations ranging from 0.002 to 0.2 mg/ml. As in the 
case of the highest HSA concentration, at the lowest TiO2 (rutile) concentration the 
presence of particles of about 7 nm caused a shift in the average diameter. At a TiO2 
(rutile) concentration of 2 mg/ml, the average diameter and the PdI value were 
increased. However, this increase in particle size could be avoided by increasing the 
amount of HSA by 10 times in the dispersion (Fig. 21, 22). 
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Fig. 21. TiO2 (rutile) particle size in dispersions at different TiO2 concentrations. TiO2 
(rutile) dispersed in distilled water at concentrations ranging from 0.002 to 2 mg/ml 
was sonicated and before concentrated PBS 1.5 mg/ml HSA was added to the 
dispersion. TiO2 (rutile) dispersions at a concentration of 2 mg/ml were also prepared 
in the same way but with the addition of 10 times more (15 mg/ml) HSA (hatched bar). 
The average hydrodynamic diameter of the particles was measured. The experiments 
were carried out in triplicate (*, p < 0.05 vs. dispersion with 2 mg/ml TiO2 (rutile)). 
(Bihari et al. 2008b) 
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Fig. 22. Polydispersity index of TiO2 (rutile) dispersions with different TiO2 
concentrations. TiO2 (rutile) dispersed in distilled water at concentrations ranging from 
0.002 to 2 mg/ml was sonicated and before concentrated PBS 1.5 mg/ml HSA was 
added to the dispersion. TiO2 (rutile) dispersions at a concentration of 2 mg/ml were 
also prepared in the same way but with addition of 10 times more (15 mg/ml) HSA 
(hatched bar). The polydispersity index (PdI) of the particles was measured. The 
experiments were carried out in triplicate (*, p < 0.05 vs. dispersion with 2 mg/ml TiO2 
(rutile)). (Bihari et al. 2008b) 
 
e) Stability 
The stability of the TiO2 (rutile) dispersions prepared with 1.5 mg/ml HSA was 
determined over a time period of one week (Fig. 23). During this period, the TiO2 
(rutile) PBS dispersions prepared with HSA remained stable without coarse 
agglomerates, whereas in dispersions without HSA the average diameter and the PdI 
values  continuously  increased, approaching a plateau at 24 hours. 
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Fig. 23. Stability of TiO2 (rutile) dispersions. TiO2 (rutile) dispersions were prepared in 
distilled water at a concentration of 0.02 mg/ml with (closed circles) or without (open 
circles) addition of HSA, before giving concentrated PBS to the dispersion. The average 
hydrodynamic diameter of the particles was measured at different time points for up to 
one week. The experiments were carried out in triplicate (*, p < 0.05, dispersions with 
vs. without HSA at the same time point). (Bihari et al. 2008b) 
 
f) Different types of nanoparticles 
To test the applicability of our optimised method for other nanoparticles and to 
physically characterise these nanoparticle dispersions, we prepared and measured TiO2 
(anatase), ZnO, SWNT, MWNT, Silver, SiOx, and nanosized DEP using HSA, Tween 
80, or mouse serum as dispersion stabilizers (Tab. 5). In all dispersions, the average 
diameter of the particles was greater then the size of the primary particles given by the 
manufacturer, indicating the presence of some agglomerates. For all nanoparticles 
tested, the addition of HSA, Tween 80, or mouse serum resulted in a decreased average 
diameter. With HSA as dispersion stabilizer, the average diameter of TiO2 (rutile), ZnO, 
SWNT, MWNT, Silver, SiOx, and DEP was below 290 nm. For TiO2 (anatase) particles, 
our method was less effective as indicated by a higher average diameter of the particles. 
In dispersions of SWNT, MWNT, and SiOx nanoparticles, the PdI value was rather 
high. 
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Table 5. Size and zeta potential data of different types of nanoparticles. Nanoparticles 
were prepared in distilled water at a concentration of 0.02 mg/ml with (DI H2O) or 
without (DI H2O no US) sonication. For other measurements, nanoparticles were 
prepared in distilled water at a concentration of 0.02 mg/ml by sonication and addition 
of human serum albumin (PBS, HSA), Tween 80 (PBS, Tween), mouse serum (PBS, 
mserum) or distilled water (PBS) previous to addition of PBS. The measurements were 
made in triplicate. The average value (bold text) and the standard deviation (normal 
text) of the measurements are shown. (Bihari et al. 2008b) 
Particle 
Average 
Diameter 
(nm) PdI 
Zeta- 
Potential 
(mV) 
Electrophoretic 
Mobility 
(µmcm/Vs) 
Conductivity 
(mS/cm) 
TiO2 (rutile) (~10 nm × 40 nm) 
DI H2O no US 502 0.434 -44.2 -3.465 0.003 
 34 0.086 0.3 0.018 0.000 
DI H2O 160 0.166 -40.9 -3.210 0.005 
 2 0.015 3.0 0.238 0.002 
PBS 641 0.263 -19.5 -1.531 18.200 
 69 0.022 6.3 0.493 0.265 
PBS, HSA 186 0.212 -8.8 -0.687 17.500 
 10 0.030 0.9 0.067 0.436 
PBS, Tween 578 0.248 -13.3 -1.041 17.900 
 132 0.017 4.4 0.347 0.173 
PBS, mserum 175 0.270 -10.7 -0.836 18.100 
 5 0.046 1.5 0.115 0.656 
DEP - SRM 2975 (mean diameter by volume distribution: 31.9 ± 0.6 µm) 
DI H2O no US 347 0.397 -45.2 -3.543 0.004 
 21 0.047 2.7 0.215 0.001 
DI H2O 144 0.132 -48.4 -3.791 0.011 
 1 0.009 1.7 0.129 0.010 
PBS 684 0.249 -32.0 -2.511 18.233 
 284 0.064 2.8 0.224 0.351 
PBS, HSA 163 0.152 -9.6 -0.750 17.967 
 3 0.008 0.6 0.043 0.321 
PBS, Tween 151 0.143 -7.0 -0.551 17.333 
 1 0.012 0.2 0.015 0.289 
PBS, mserum  168 0.209 -9.2 -0.722 18.233 
 13 0.033 1.4 0.111 0.289 
Silver (30-50 nm) 
DI H2O no US 403 0.455 -20.1 -1.580 0.012 
 125 0.039 3.9 0.308 0.009 
DI H2O 161 0.338 -29.8 -2.337 0.003 
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Particle 
Average 
Diameter 
(nm) PdI 
Zeta- 
Potential 
(mV) 
Electrophoretic 
Mobility 
(µmcm/Vs) 
Conductivity 
(mS/cm) 
 12 0.055 0.3 0.026 0.002 
PBS 223 0.343 -24.5 -1.919 17.933 
 8 0.026 3.1 0.243 0.961 
PBS, HSA 172 0.343 -11.3 -0.889 18.167 
 22 0.018 0.3 0.020 0.153 
PBS, Tween 194 0.368 -9.8 -0.765 17.267 
 23 0.014 1.9 0.145 0.252 
PBS, mserum 158 0.305 -11.0 -0.863 18.333 
 5 0.063 0.6 0.045 0.289 
TiO2 (anatase) (<25 nm) 
DI H2O no US 1169 0.462 13.8 1.084 0.011 
 48 0.020 2.1 0.162 0.011 
DI H2O 517 0.431 -18.7 -1.467 0.012 
 60 0.055 0.4 0.035 0.012 
PBS 890 0.369 -23.0 -1.805 17.700 
 230 0.077 1.7 0.132 0.458 
PBS, HSA 521 0.475 -9.6 -0.749 18.733 
 25 0.023 1.1 0.088 0.709 
PBS, Tween 818 0.358 -14.0 -1.096 17.633 
 11 0.029 2.5 0.200 0.513 
PBS, mserum 574 0.474 -10.7 -0.841 18.300 
 92 0.111 1.1 0.090 0.964 
ZnO (<100 nm) 
DI H2O no US 1298 0.721 10.6 0.832 0.008 
 252 0.072 2.0 0.157 0.001 
DI H2O 278 0.414 -29.4 -2.301 0.015 
 72 0.086 6.0 0.475 0.004 
PBS 517 0.445 -29.3 -2.294 17.967 
 174 0.053 2.8 0.219 0.462 
PBS, HSA 267 0.288 -11.6 -0.907 18.300 
 6 0.059 0.6 0.045 0.500 
PBS, Tween 457 0.360 -14.6 -1.148 18.000 
 135 0.041 7.3 0.570 0.265 
PBS, mserum 190 0.544 -7.7 -0.603 18.033 
 8 0.103 1.1 0.090 0.231 
SiOx (15nm) 
DI H2O no US 1121 0.593 -33.4 -2.616 0.021 
 304 0.014 1.8 0.136 0.010 
DI H2O 370 0.488 -21.1 -1.655 0.004 
 49 0.047 19.8 1.551 0.005 
PBS 852 0.617 -14.5 -1.135 17.867 
 267 0.025 0.2 0.015 0.058 
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Particle 
Average 
Diameter 
(nm) PdI 
Zeta- 
Potential 
(mV) 
Electrophoretic 
Mobility 
(µmcm/Vs) 
Conductivity 
(mS/cm) 
PBS, HSA 251 0.880 -10.4 -0.815 18.533 
 27 0.107 0.7 0.052 0.153 
PBS, Tween 398 0.532 -3.7 -0.288 17.900 
 51 0.040 0.4 0.029 0.200 
PBS, mserum 132 0.497 -11.1 -0.868 19.100 
 49 0.192 0.6 0.044 0.265 
SWNT (outer diameter: <2nm, length: 1-5µm) 
DI H2O no US 689 0.569 -7.0 -0.550 0.010 
 111 0.100 7.6 0.595 0.009 
DI H2O 372 0.560 -23.1 -1.814 0.004 
 59 0.076 10.4 0.813 0.001 
PBS 977 0.526 -2.6 -0.203 11.533 
 46 0.131 2.3 0.178 9.989 
PBS, HSA 285 0.605 -10.1 -0.790 17.600 
 79 0.143 0.7 0.054 0.400 
PBS, Tween 291 0.531 -8.5 -0.667 16.933 
 89 0.103 3.3 0.259 1.124 
PBS, mserum 115 0.666 -7.7 -0.602 18.433 
 51 0.132 1.6 0.126 1.168 
MWNT (outer diameter: 10-30 nm, lengths: 1-2µm) 
DI H2O no US 309 0.304 -2.7 -0.215 0.007 
 48 0.027 2.2 0.175 0.005 
DI H2O 262 0.397 -22.5 -1.765 0.004 
 101 0.048 19.2 1.502 0.003 
PBS 486 0.424 -19.6 -1.535 18.000 
 173 0.079 5.8 0.458 0.608 
PBS, HSA 269 0.406 -9.7 -0.760 19.733 
 56 0.027 1.1 0.087 2.136 
PBS, Tween 206 0.292 -4.8 -0.375 17.733 
 13 0.037 0.5 0.039 0.208 
PBS, mserum 166 0.415 -7.8 -0.610 18.233 
 10 0.006 0.4 0.029 0.666 
TiO2 (rutile, NA) (30-40 nm) 
DI H2O no US 1702 0.351 -34.5 -2.708 0.016 
 372 0.290 3.8 0.300 0.013 
DI H2O 418 0.306 -29.5 -2.312 0.016 
 2 0.008 3.0 0.235 0.008 
PBS 617 0.305 -20.6 -1.615 16.800 
 99 0.037 1.0 0.076 0.200 
PBS, HSA 414 0.319 -11.5 -0.899 17.667 
 17 0.038 1.5 0.117 0.473 
PBS, Tween 663 0.291 -12.1 -0.946 17.933 
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Particle 
Average 
Diameter 
(nm) PdI 
Zeta- 
Potential 
(mV) 
Electrophoretic 
Mobility 
(µmcm/Vs) 
Conductivity 
(mS/cm) 
 123 0.016 4.4 0.343 0.351 
PBS, mserum 548 0.358 -10.7 -0.842 18.433 
 78 0.092 1.3 0.099 0.231 
 
g) Zeta potential 
All particles had a negative zeta potential in distilled water after sonication (Table 5). 
Interestingly, ZnO, and TiO2 (anatase) had a positive zeta potential upon dispersion in 
distilled water and became negative after sonication. The particles were less negative 
when prepared with HSA, Tween 80, or serum in PBS. TiO2 (rutile) prepared with HSA 
in RPMI cell culture medium had a positive zeta potential (data not shown). 
 
h) Transmission electron microscopy 
To visualize nanoparticles in dispersions, we used transmission electron microscopy. 
Similarly to the dynamic light scattering measurements, transmission electron 
microscope images showed smaller nanoparticle agglomerates in dispersions prepared 
with HSA or mouse serum as stabilizers (Fig. 24, 25, 26). In the case of TiO2 (rutile) 
dispersions prepared with HSA, we determined the particle size with an image 
analysing software. The mean particle size was 134 ± 71 nm. 
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Fig. 24. Electron microscopy of titanium dioxide (rutile and anatase) nanoparticles. 
Magnification: 100,000 (950 × 950 nm) Nanoparticle dispersions were prepared in 
distilled water at a concentration of 0.02 mg/ml without stabilizer (PBS) or with the 
addition of human serum albumin (+HSA) or mouse serum (+Serum) before giving 
concentrated PBS to the dispersion. (Bihari et al. 2008b) 
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Fig. 25.  Electron microscopy of zinc oxide, silicon oxide, and silver nanoparticles. 
Magnification: 100,000 (950 × 950 nm)  ZnO, SiOx and silver nanoparticle dispersions 
were prepared in distilled water at a concentration of 0.02 mg/ml without stabilizer 
(PBS) or with the addition of human serum albumin (+HSA) or mouse serum (+Serum) 
before giving concentrated PBS to the dispersion. (Bihari et al. 2008b) 
 
DOI:10.14753/SE.2016.1824
 73 
 
Fig. 26. Electron microscopy of nanotubes and diesel exhaust particles. Magnification: 
100,000 (950 × 950 nm) SWNT, MWNT and diesel exhaust particle (SRM 2975) 
dispersions were prepared in distilled water at a concentration of 0.02 mg/ml without 
stabilizer (PBS) or with the addition of mouse serum (+serum) or human serum albumin 
(+HSA) before giving concentrated PBS to the dispersion. (Bihari et al. 2008b) 
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2. Optimisation of platelet-granulocyte complex measurement 
 
a) Flow cytometric analysis of platelet-granulocyte coincidence 
To model platelet-granulocyte coincidence experimentally, the mixture of two non-
interacting fluorescent beads was measured at various dilutions. FITC-labelled beads 
with fluorescent signals for the FL1 detector of the flow cytometer were given at a 
higher concentration representing platelets and Starfire Red™-labelled beads with 
fluorescent signals for the FL3 detector were given at a lower concentration 
representing leukocytes. Fig. 27 shows the average percentage of FL1 and FL3 double 
positivity among the FL3 positive events as a function of dilution. The value of double 
positivity (mean ± SD) changes between 37.3 ± 1.3% and 2.1 ± 0.2% with the sample 
dilution in the range of 10–320 fold. This means that coincidence occurs often at low 
dilutions and that the rate of coincidence decreases exponentially with increasing 
dilution.  
 
 
Fig. 27. Percentage of average double positivity ± standard deviation (n = 4) measured 
in the mixture of FITC (FL1) and Starfire Red (FL3) labelled non-interacting 
fluorescent beads as a function of sample dilution. Data collection was triggered by 
FL3 signal. (Bihari et al. 2008a) 
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To further analyse coincidence, data were transformed according to Eq. (10) (see 
section IV/6/b) 
(10) ( )100/1ln DY −= , 
where D means the percentage of platelet marker-positive events in the granulocyte 
gate. As described in the Methods section, this transformation should result in a straight 
line. The intercept contains information on the amount of dilution-resistant stable 
complexes and the negative slope of the straight line equals the detection volume. Fig. 
28 shows the transformed data as a function of FITC (FL1) labelled bead concentration. 
Data of each dilution series transformed according to Eq. (10) result in straight lines as 
well (r2 > 0.999, p < 0.001). None of the intercepts of these straight lines differ from 
zero at 95% confidence level as judged by regression analysis. The average detection 
volume (mean ± SD) calculated from the slopes of the individual straight lines is 
20.4 ± 1.0 pl. 
 
 
Fig. 28.  Data of Fig. 27 transformed according to Eq. (10) (n = 4) as a function of 
FITC (FL1) labelled bead concentration. (Bihari et al. 2008a) 
 
After modelling coincidence by fluorescent beads, the coincidence of platelets and 
leukocytes was studied in EDTA-anticoagulated blood. EDTA is known to inhibit 
formation of platelet-granulocyte complexes (Hamburger and McEver 1990), thus 
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double positivity should originate only from coinciding platelets (labelled with CD41-
FITC) and granulocyte (labelled with CD15-PC5). 
When EDTA-anticoagulated blood of our healthy donors (platelet concentration: 
254 ± 36 G/l) was diluted 6.7–320 fold, the percentage of CD15/CD41 double-positive 
events among the CD15+ events exhibited a similar concentration dependence as that of 
the bead mixture (Fig. 29). 
 
 
Fig. 29. Average percentage with standard deviation of CD41/CD15 double positivity 
among CD15 positive events as a function of dilution (n = 7) for EDTA anticoagulated 
blood samples. Data collection was triggered by FL3 (CD15) signal. (Bihari et al. 
2008a) 
 
In Fig. 30 the natural logarithm of ratios of CD41 negative events in the granulocyte 
gate is plotted as a function of platelet concentration for the EDTA anticoagulated blood 
samples of our donors (cf. Eq. (10)). All seven data sets can be fitted with straight lines 
(p < 0.001; the minimum of r2 is 0.996). From the slopes of these lines the average 
detection volume for the EDTA anticoagulated blood in the dilution range tested is 
13.5 ± 1.6 pl. The intercepts of these straight lines do not deviate significantly from zero 
at p < 0.01 significance level for four of our donors as judged by regression analysis. 
However, it is noteworthy that three of our donors exhibited a non-zero intercept, which 
indicates the presence of 5.7 ± 0.7 % of stable complexes (cf. Eq. (8)). 
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Fig. 30. Individual data of CD41/CD15 double positivity measured in EDTA 
anticoagulated blood samples of our seven donors transformed according to Eq. (10) as 
a function of platelet concentration. (Bihari et al. 2008a) 
In the next set of experiments, paraformaldehyde-treated citrated blood samples 
were studied, in which also real platelet-granulocyte complexes exist. To be able to 
distinguish between double positivity originating from real platelet-granulocyte 
complexes and from coincidence, two different stainings were applied for each blood 
sample. To measure all double-positive events, platelets (CD41 FITC) and leukocytes 
(CD15 PC5) were stained. To measure coincidence, platelets (CD41 FITC) were stained 
and instead of staining leukocytes, FL3 fluorescent beads were given to blood. Fig. 31 
shows a representative data set of donor #2 at various dilutions. CD 41 positivity 
measured as a function of dilution exhibits similar concentration dependencies whether 
data collection is triggered by fluorescent beads (open circles) or fluorescent-labelled 
granulocytes (solid squares). CD 41 positivity is always higher when data collection is 
triggered by granulocytes than in the case of beads. Data of Fig. 31 after transformation 
according to Eq. (10) result in two straight lines (Fig. 32): one having a practically zero 
intercept (beads in the sample, which do not interact with platelets), the other having a 
non-zero intercept indicating the presence of dilution independent stable complexes. 
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Fig. 31. Percentage of platelet–granulocyte (solid squares) and platelet-bead (open 
circles) double positive data as a function of sample dilution measured in 
paraformaldehyde-treated citrated blood samples of donor #2. Data collection was 
triggered by FL3 signal. (Bihari et al. 2008a) 
 
 
Fig. 32. Platelet–granulocyte (solid squares) and platelet-bead (open circles) data of 
Fig. 31 transformed according to Eq. (10) as a function of platelet concentration. 
(Bihari et al. 2008a) 
 
The same qualitative results were obtained for each of our donors. Straight lines 
obtained from the data of our seven donors measured either with or without beads have 
a correlation coefficient of at least 0.992. Straight lines representing bead-containing 
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samples have practically zero intercepts (mean ± SD = − 0.006 ± 0.006) which means 
that no more than 0.61 ± 0.64 % of beads are positive for platelet markers. Slopes of the 
corresponding straight line pairs for each donor are identical within the limit of error, 
which means that the detection volume does not change when one replaces the 
granulocyte trigger with the bead one. The average detection volume when granulocytes 
or beads are used as triggers is: Vd =  15.2 ± 1.7 pl and 15.0 ± 1.9 pL, respectively. 
 
b) Mathematical description of platelet-granulocyte complexes 
The experiments outlined above provide the means to estimate the percentage of 
complexes at any platelet concentration. Let C denote the concentration of complexes, 
and Db and Dg the percentage of CD41 positive events at the same dilution, in the case 
when FL3 bead or granulocyte fluorescence were used as triggers, respectively. 
According to Eqs. (8) and (9) ( see section IV/6/b) one gets: 
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Combining the two above equations, the percentage of platelet–granulocyte complexes 
(Dr) among granulocytes can be calculated: 
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This simple formula is applicable to any blood dilution using CD41 positive data pairs 
(Dg and Db) in the case when event collection is triggered alternately by granulocytes 
and beads. 
 
According to our experience for a given donor, Dr is constant within the limit of error at 
each dilution of the paraformaldehyde treated blood samples (see Table 6). 
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Table 6. The amount of stable complexes in the paraformaldehyde-treated citrated 
blood of the individual donors expressed as a percentage of granulocytes (Dr). The 
averages and standard deviations for each individual donor were calculated from 
values obtained at six different dilutions. (Bihari et al. 2008a) 
Donor #1 #2 #3 #4 #5 #6 #7 #8 #9 
Dr 17.6 5.9 18.6 30.8 0.5 18.1 15.0 10.1 16.2 
SD 1.6 0.7 1.2 0.5 0.4 1.1 1.1 0.8 0.7 
 
3. Effect of nanoparticles on platelet activation in vitro 
 
a) Platelet P-selectin expression  
Human platelet P-selectin expression was measured to analyse the direct effects of 
nanoparticles on platelet activation. Carboxyl-modified polystyrene, DEP, and TiO2 
(rutile) nanoparticles did not change CD62P (P-selectin) expression on platelets as 
compared to controls. In contrast, the addition of ADP, amine-modified polystyrene, or 
SWNT nanoparticles to human whole blood increased P-selectin expression on platelets 
(Fig 33).  
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Fig. 33. A. Representative flow cytometry histograms of platelet P-selectin 
measurements after 10 minutes incubation of human whole blood, either with PBS 
(dashed line), or with 1 µM ADP (thick solid line) or with 100 µg/ml SWNT (thin solid 
line). B. Platelet P-selectin expression. Human whole blood was incubated with PBS 
(n=44), ADP (n=44) or nanoparticle dispersion for 10 minutes. The concentrations of 
amine- (n=23), carboxyl-modified polystyrene (n=18), DEP (n=16), or TiO2 rutile 
(n=15) nanoparticles were 100 µg/ml each. SWNT concentrations were 1 µg/ml (n=11), 
10 µg/ml (n=14) and 100 µg/ml (n=25). ADP was added at a final concentration of 1 
µM. Mean CD62P fluorescence intensities (MFI) of CD41-positive events were 
analysed (*, p<0.05 vs. control). (Bihari et al. 2010) 
 
b) Platelet-granulocyte complexes 
As an additional marker of platelet activation, the formation of platelet-granulocyte 
complexes was analysed. Similar to the results of the P-selectin expression 
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measurements, ADP, amine-modified polystyrene, and SWNT nanoparticles 
significantly increased the percentage of CD41 positivity in the granulocyte gate as 
compared to control experiments. In contrast, carboxyl-modified polystyrene, DEP, and 
TiO2 (rutile) nanoparticles had no effect on the number of platelet-granulocyte 
complexes (Fig 34). 
 
 
Fig. 34. A. Representative flow cytometry histograms of platelet-granulocyte complexes 
measured in human whole blood after incubation with PBS (dashed line), 1µM ADP 
(thick solid line), or 100 µg/ml SWNT (thin solid line) for 10 minutes. B. Platelet-
granulocyte complexes. Human whole blood was incubated with PBS (n=16), ADP 
(n=16), or nanoparticles for 10 minutes. The concentration of amine- (n=9), carboxyl- 
(n=9) modified polystyrene, DEP (n=9), TiO2 rutile (n=9) or SWNT (n=10) 
nanoparticles was 100 µg/ml. ADP was given at a final concentration of 1 µM. 
(*, p<0.05 vs. control). (Bihari et al. 2010) 
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c) Platelet aggregometry 
To further characterize platelet activation induced by amine-modified polystyrene and 
SWNT nanoparticles, the effect of these nanoparticles on human platelet aggregation 
was analysed. The addition of SWNT nanoparticles to PRP reduced the optical density 
as compared to PPP incubated with SWNT. Changes in the optical density after the 
addition of amine-modified polystyrene beads were below the threshold of background 
noise (Fig 35). It is noteworthy that in case of SWNT we could not detect the usual 
initial increase in optical density due to platelet shape change and that the optical 
density change was not as rapid as by ADP-induced platelet aggregation (Fig 36). 
 
 
Fig. 35. Platelet aggregation. Optical density changes of PRP versus PPP were 
measured after addition of amine-modified polystyrene (n=18) or SWNT (n=13) 
nanoparticles to both solutions. The final concentrations of nanoparticles were 100 
µg/ml. After running samples for at least 10 minutes, ADP was added at a final 
concentration of 1 μM to PRP. Aggregation in the presence of nanoparticles is given as 
a percentage of that induced by ADP (*, p<0.05 vs. zero). (Bihari et al. 2010) 
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Fig. 36. Platelet aggregation curves from three representative experiments. Optical 
density changes of PRP versus PPP were measured after the addition of PBS (1), 
amine-modified polystyrene (2), or SWNT (3) nanoparticles to both solutions. The final 
concentrations of nanoparticles were 100 µg/ml. After running samples for at least 10 
minutes, ADP was added at a final concentration of 1 μM to PRP (arrow). Slightly 
modified after Bihari et al. (Bihari et al. 2010) 
 
4.  Effect of nanoparticles on thrombus formation in vivo 
 
a) Mouse blood counts 
There were no differences in platelet, leukocyte, and erythrocyte counts, haematocrit, 
haemoglobin concentration, mean corpuscular volume, mean corpuscular haemoglobin, 
and mean corpuscular haemoglobin concentration of erythrocytes among groups treated 
with vehicle or nanoparticles (data not shown). 
 
b) Mesenteric thrombosis 
The effect of nanoparticles on thrombus formation were analysed in small mesenteric 
arteries. As a positive control, systemic administration of epinephrine significantly 
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decreased the cessation time compared to that which occurred when physiological saline 
was injected. Amine-modified polystyrene nanoparticles significantly decreased and 
carboxyl-modified polystyrene nanoparticles significantly increased the cessation time 
compared to that of the controls (Fig 37). 
There were no significant differences in arterial cessation time in case of DEP-, 
TiO2 (rutile)- or vehicle-treated animals. In contrast, cessation time was significantly 
decreased in SWNT- compared to vehicle-treated animals (Fig 38). 
 
 
Fig. 37. Cessation time in small mesenteric arteries after induction of ferric chloride-
induced thrombosis. Epinephrine was given at a blood concentration of 12.5 µM intra-
arterially immediately before thrombosis induction. Amine- or carboxyl-modified 
polystyrene nanoparticles at a concentration of 0.5 mg/kg body weight or physiological 
saline (control) were administered intra-arterially 10 minutes prior to the induction of 
thrombosis. (n=8; *, p<0.05 vs. control). (Bihari et al. 2010) 
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Fig. 38. Cessation time in small mesenteric arteries after induction of ferric chloride-
induced thrombosis. DEP, TiO2 (rutile) or SWNT nanoparticles at a concentration of 1 
mg/kg body weight or vehicle were administered intra-arterially 10 minutes before 
thrombosis induction. (n=8; *, p<0.05 vs. vehicle). (Bihari et al. 2010) 
 
c) Cremasteric thrombosis  
Microvascular thrombotic effects of nanoparticles were analysed in the cremasteric 
microcirculation of mice. To ensure comparable intravascular FITC dextran 
concentrations in all experiments, the fluorescence intensity was measured in one 
venule in each experiment. There were no significant differences in the fluorescent 
intensities among experimental groups (data not shown). As a positive control, LPS 
significantly decreased the onset time and the cessation time in arterioles. In contrast to 
the small mesenteric arteries, onset and cessation times in arterioles of mice treated with 
amine- or carboxyl-modified polystyrene nanoparticles were the same as in the control 
groups (Fig 39). Furthermore, no significant differences were found in the onset time of 
thrombus formation in arterioles.  
While the cessation times were not changed upon the application of DEP or TiO2 
(rutile), SWNT injection decreased the cessation time in arterioles dose-dependently as 
compared to the vehicle control. (Fig 40). Interestingly, no significant differences were 
found in venous thrombosis parameters (data not shown). 
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Fig. 39. Light/dye-induced thrombosis in cremasteric arterioles. LPS (4 mg/kg body 
weight) was given i.p. 4 hours prior to the induction of thrombosis. Amine- or carboxyl-
modified polystyrene nanoparticles at a concentration of 0.5 mg/kg body weight or 
physiological saline (control) were administered intra-arterially 10 minutes prior to the 
induction of thrombosis. Onset (black) and cessation times (grey) are shown. (n=8; *, 
p<0.05 vs. control). (Bihari et al. 2010) 
 
 
Fig. 40. Light/dye-induced thrombosis in cremasteric arterioles. DEP, TiO2 (rutile), 
nanoparticles at a concentration of 1 mg/kg body weight, SWNT at concentrations of 
0.01, 0.1, 1 mg/kg body weight or vehicle were administered intra-arterially 10 minutes 
prior to the induction of thrombosis. Onset (black) and cessation times (grey) are 
shown. (n=8; *, p<0.05 vs. vehicle). (Bihari et al. 2010) 
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VI. Discussion 
The main goal of this dissertation was to analyse the influence of nanoparticles on 
platelet activation in vitro and on thrombus formation in vivo.  In order to be able to 
carry out these measurements, we had to solve two problems: optimisation of the 
dispersion method of nanoparticles and optimisation of the platelet-granulocyte 
complex measurement. The discussion section begins with the consideration of these 
two methodological studies. 
 
1. Optimisation of the nanoparticle dispersion method  
To determine the toxicity of nanoparticles in biological in vitro or in vivo settings, the 
particles first have to be dispersed in a physiological fluid medium that is compatible 
with the biological material. Nanoparticles, however, tend to build coarse agglomerates 
in physiological solutions This phenomenon is described by the DLVO (named after 
Derjaguin, Landau, Verwey, Overbeek) theory: the stability of a particle dispersion 
depends on the balance between attractive (van der Waals) and repulsive (electrostatic) 
forces between particles (Müller 1996). Based on this theory, colloid science describes 
two fundamental ways for stabilising a dispersion: electrostatic and steric stabilisation 
(Fig 41). For the electrostatic stabilisation, the zeta potential of the electrostatic double 
layer around the particles provides repulsive forces. In practice, if the zeta potential of 
the particles is lower than -30 mV or higher than +30 mV, the repulsive forces are high 
enough to stabilise the dispersion. However, the zeta potential of the particles strongly 
depends on the pH and ionic strength of the dispersion medium (Müller 1996). At 
physiological pH and physiologic ionic strength, electrostatic repulsive forces are 
usually not high enough to stabilise the dispersion, and the nanoparticles form coarse 
agglomerates (Buford et al. 2007, Deguchi et al. 2007, Murdock et al. 2008). The other 
way of dispersion stabilisation is steric stabilisation, by which polymeric molecules are 
adsorbed onto the surface of nanoparticles preventing them from getting close to each 
other. As this kind of stabilisation is not dependent on the zeta potential of particles, i.e. 
the stability of the dispersion is independent of pH and ionic strength, it can also work 
in physiological solutions (Powers et al. 2006). This strategy has been found to be 
beneficial in different studies. Pulmonary surfactant, bronchoalveolar lavage fluid, 
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Tween, albumin, or serum were used as dispersion stabilising polymeric molecules to 
decrease the formation of coarse agglomerates (Buford et al. 2007, Sager et al. 2007, 
Murdock et al. 2008). 
 
 
Fig. 41. Electrostatic versus steric stabilisation of nanoparticle dispersions. Repulsive 
forces are given in electrostatic stabilisation by the zeta potential, whereas in steric 
stabilisation by the adsorbed molecules on the nanoparticle surface.  
 
Our aim was to optimise the factors that might influence the effectiveness of 
dispersing nanoparticles in physiological solutions using steric stabilisation, such as the 
ultrasound energy levels, various dispersion stabilizers (HSA, BSA, MSA, Tween 80, or 
mouse serum) at various concentrations and at different nanoparticle concentrations, 
and different sequences of preparation steps. We also tested our method on a broad 
range of different types of nanoparticles and measured the stability of the dispersion 
over time. 
To analyse the effectiveness of steric stabilisation, we measured the size of 
nanoparticles in the dispersion with dynamic light scattering. This method was found to 
be reliable for measuring particle size and size distribution of dispersed spherical 
nanomaterials (Powers et al. 2006). Additionally, we measured the zeta potential of the 
particles with phase analysis light scattering and visualised dispersed nanoparticles 
using transmission electron microscopy. 
First, we measured the effect of different sonication energies. Ultrasound heats up 
the fluid locally and generates steam bubbles (cavities). The rapid collapse of such gas 
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bubbles (implosion) gives rise to extremely high pressure waves. The energy of the 
pressure waves can break up nanoparticle agglomerates. It is known that the result of 
sonication, e.g. particle size reduction, depends on the applied energy per volume of the 
dispersion (specific energy) (Pohl et al. 2004, Hilscher 2005). The difficulty is that the 
sonication energy should be high enough to deagglomerate the particles, but at the same 
time it must not destroy them. We found that after rapid initial size reduction, a further 
increase in the specific energy did not lead to further reduction of the particle size. 
Thus, a specific energy of 4.2 × 105 kJ/m3 was optimal for deagglomerating the 
nanoparticles. Our findings confirm previous observations of Mandzy et al. (Mandzy et 
al. 2005). 
In the next set of experiments, we analysed the optimal sequence of particle 
preparation. The best sequence of dispersion preparation was when we first sonicated 
the nanoparticles, then added HSA as stabilizer, and finally added PBS to the 
dispersion. The addition of HSA molecules after sonication prevents the particles from 
the reagglomeration. Similar results were published for the preparation of dispersions of 
C60 nanoparticles (Deguchi et al. 2007). We found that the stabilising effect of albumin 
was species-independent as the agglomeration of nanoparticles could be avoided by the 
addition of either HSA, or MSA, or BSA; and it was also medium-independent since 
HSA worked in PBS as well as in RPMI cell culture medium. 
When HSA molecules are added to the nanoparticles, they adhere to the surface of 
the particles, as indicated by a significant increase in the average diameter of the 
particles. This finding is in agreement with the prevailing opinion on the formation of a 
protein corona (Lynch and Dawson 2008) (see section II/2/e). Interestingly, in our 
measurements, the difference in average particle size between dispersions with and 
without HSA was 14.5 nm, consistent with approximately twice the diameter of one 
HSA molecule (7.1 ± 0.1 nm, our measurement with dynamic light scattering). These 
data suggest that the HSA molecules may completely cover the nanoparticles. 
Furthermore, the zeta potentials of different nanoparticles, ranging from -48.4 mV to -
18.7 mV in distilled water, change uniformly to a value of about -10 mV after the 
addition of HSA (see Table 5). This change is presumably due to HSA molecules 
covering nanoparticles and masking their own zeta potential. Thus, the particles have a 
zeta potential near to the zeta potential of HSA (the zeta potential of the HSA molecules 
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in PBS is about -6 mV). This finding is corroborated by data from Lindman et al. 
(Lindman et al. 2007) who found, using the isothermal titration calorimetry technique, 
that particles with a diameter larger than 120 nm are covered with a dense monolayer of 
proteins. 
To further analyse nanoparticle-albumin interactions, dispersions with different 
particle and albumin concentrations were prepared. HSA in a concentration higher than 
0.015 mg/ml prevented the formation of coarse agglomerates, when the TiO2 (rutile) 
concentration was 0.02 mg/ml. Elevating the HSA concentration in the dispersion 
resulted in a dose-dependent increase of particle size, obviously because the albumin 
layer on the nanoparticles was becoming complete. Further increase of the HSA 
concentration to 15 mg/ml results in saturation of the protein corona on the nanoparticle 
surface and the amount of free albumin molecules is high enough to be detectable as a 
separate peak in the size distribution measurements. From these experiments we could 
determine that the lowest HSA/TiO2 (rutile) concentration ratio, at which particles are 
covered with HSA and dispersion is stable, was 0.75. We calculated that there are 
~33000 HSA molecules per each TiO2 (rutile) particle in the dispersion. This is ~7 times 
more than the amount calculated as necessary for a 100% HSA coverage of 200 nm 
spherical particles (4650 HSA molecules/particle) (Lindman et al. 2007). When we 
increase the TiO2 (rutile) concentration 10-fold but use the same HSA concentration, the 
amount of HSA molecules is not high enough to cover TiO2 (rutile) particles, resulting 
in insufficient protection against the agglomeration of particles. Consistent with this 
theory, we detected coarse agglomerates in that dispersion. However, when we 
increased the TiO2 (rutile) and HSA concentrations equally (10-fold), generating the 
same HSA/TiO2 (rutile) surface area ratio, the dispersion lacked the coarse 
agglomerates. These data suggest that the total surface area of particles in the dispersion 
determine the required amount of stabilizer. Thus, based on our measurements, for a 
nanoparticle concentration range relevant for toxicological studies (0.002 mg/ml – 0.2 
mg/ml), we found 1.5 mg/ml HSA to be the optimal concentration to prevent formation 
of coarse agglomerates in the dispersion.  
Adding mouse serum (30 μl mouse serum to 1 ml dispersion) to the dispersion 
containing similar amount of albumin when HSA was used also prevented the formation 
of coarse agglomerates. Thus, this amount of serum contains abundant proteins to cover 
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the particle surfaces. This is also supported by the publication of Cedervall et al., 
describing that ~100 μl plasma saturates 1 mg of 200 nm particles (Cedervall et al. 
2007a), which is a similar concentration to the ones that we used. 
Next we analysed whether particles prepared with HSA gave a stable dispersion. 
TiO2 (rutile) prepared with HSA was found to be stable for at least one week, whereas 
without stabilizer the particles started to form agglomerates in PBS. Similar results were 
published for other particles (Deguchi et al. 2007). 
We found that our optimised method was suitable for preparing dispersions without 
coarse agglomerates (average diameter < 290 nm) from nanosized TiO2 (rutile), ZnO, 
Ag, SWNT, MWNT, and DEP (SRM2975). We measured high PdI values for SWNT, 
MWNT, and SiOx. In the case of nanotubes, the size parameter should be interpreted 
differently from that of other particles since nanotubes have higher aspect ratios. In this 
case, the size parameter indicates the hydrodynamic diameter of a spherical particle that 
would move in the dispersion media at the same velocity as nanotubes. Thus the high 
PdI of SWNT and MWNT nanotubes is due to the shape of these particles. Although the 
size data obtained from the measurement of nanotubes are influenced by the shape of 
these nanoparticles, dynamic light scattering gives important information about the 
agglomeration state of these dispersions. If nanotubes agglomerate, they move more 
slowly in the dispersion medium and will be detected as if they had a higher average 
diameter. In contrast, well-dispersed nanotube dispersions show a lower average 
diameter. Such a difference could be detected when we compared the dispersions 
prepared in PBS with those prepared with our optimised method (see Table 5). For SiOx 
and TiO2 (anatase) particles, our method was less effective as indicated by a relatively 
high average diameter and PdI of particles. 
The quantitative analysis of dispersions with transmission electron microscopy 
confirmed the data obtained from dynamic light scattering (see Fig. 24-26). Our 
optimised method generated an improved dispersion with any of the nanoparticles 
measured.  
Besides the described methodological considerations, there are also some other 
options that have not been tested yet, but could theoretically further improve 
nanoparticle dispersions. As nanoparticles do not need to be in a physiological solution 
at the first stage of the preparation, also non-physiological chemical techniques might 
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be used to improve the quality of the dispersion at this stage. The point is to find 
techniques or chemical reagents that help deagglomerate nanoparticles, but at the same 
time do not hamper or even augment the binding of steric stabilizer. These techniques or 
chemicals should be chosen so that they could be neutralised or removed during the last 
stage of the preparation. For example, it could be helpful to change pH to the 
electrostatic optimum of the given nanoparticles at the beginning of the preparation, 
which would strengthen the repulsive forces, and to adjust pH to the physiological level 
after the addition of steric stabiliser.  
Another option concerns sonication. After sonication, nanoparticles immediately 
start to agglomerate, and this process is stopped after the addition of a steric stabilizer. It 
is therefore important to keep this time period as short as possible. The best option for 
this is to use a second sonication step after the addition of the steric stabilizer (data not 
published). During the second sonication, the steric stabilizer is already in the 
dispersion, and this means it can immediately adhere to nanoparticle surfaces accessible 
due to deagglomeration. To avoid damage of the steric stabilizer by the second 
sonication step, less ultrasound energy, repeated short sonication periods, or cooling, 
might be necessary.  
In biological studies, when nanoparticles get into the blood circulation they come 
into contact with albumin and other serum proteins, and these proteins cover the 
nanoparticles forming a protein corona. Our optimised method also uses albumin or 
serum, thus nanoparticles dispersed with our method are covered with the same proteins 
that nanoparticles encounter in the blood. Presumably later, after injection into the 
systemic circulation, proteins with higher affinity also integrate into the protein corona 
of these nanoparticles (Lynch and Dawson 2008). 
We found that the following aspects are important in considering the preparation of 
nanoparticle dispersions in physiological solutions (Fig. 42):  
 
i) the optimal sequence is first to sonicate the nanoparticles in distilled water, 
then to add the stabilizer, and finally to add buffered salt solution to the 
dispersion 
ii) the usage of a sonication energy high enough to deagglomerate the particles 
(>4.2 × 105 kJ/m3) 
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iii) the addition of albumin or serum as stabilizers at a concentration sufficient 
to cover the nanoparticles (1.5 mg/ml HSA for dispersions with less than 0.2 
mg/ml nanoparticle concentration or serum with a similar albumin 
concentration) 
 
 
Fig. 42. Preparation steps of nanoparticle dispersion. 1. Sonicate the nanoparticles in 
distilled water (power consumption: 7 W, 1 ml dispersion, 60 sec sonication, = 
4.2 × 105 kJ/m3). 2. Add stabilizer (1.5 mg/ml HSA or an amount of serum resulting in a 
similar albumin concentration for dispersions with less than 0.2 mg/ml nanoparticle 
concentration). 3. Add concentrated PBS to achieve physiological pH and salt 
concentration. (Bihari et al. 2008b) 
 
In conclusion, the optimised dispersion method appears to be effective and practical 
for preparing dispersions of nanoparticles in physiological solutions, without creating 
coarse agglomerates. 
 
2. Optimisation of platelet-granulocyte complex measurement 
Flow cytometry is the easiest and most often used way to measure platelet-granulocyte 
complexes. Platelets and granulocytes are labelled with various antibody-bound 
fluorescent probes and analysed with a flow cytometer (Li et al. 1999, Snow 2004, Fent 
et al. 2008). Platelet-granulocyte complexes can be identified as simultaneous 
fluorescent signals from both cell types. However, based on this kind of measurement, 
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one is unable to distinguish the real platelet-granulocyte complexes from the separated 
platelets and granulocytes that coincide in the detection volume (Fig. 12). To solve this 
problem we analysed the factors determining the rate of coincidence. 
First, we measured coincidence in two different experimental models. In the first 
model, we mixed two different fluorescent beads in concentrations corresponding to 
that of platelets and granulocytes respectively. Since in this model non-interacting beads 
(Maehara et al. 1990) were used, simultaneous fluorescent signals from both types of 
beads could be detected just as in the case of coincidence. In the second model EDTA 
anticoagulated human blood was analysed, where according to literature data, in the 
absence of extracellular Ca2+, no platelet-granulocyte complexes exist (Hamburger and 
McEver 1990). In these two models, the measured double positive events could only be 
derived from coincidence. In both systems, at 10-fold dilution, which ensures the 
manufacturer's recommended flow cytometric event rate (102 – 4 × 103 particles/s), up 
to 40% double positivity was experienced (Fig. 27 and 29). When we increased the 
dilution the percentage of double positive events decreased. The dilution dependence of 
double positivity is understandable because the probability of the presence of platelets 
in the detection volume is lower in a diluted solution than in a concentrated one. In 
contrast, coincidence does not depend on granulocyte concentration, which can be 
explained by the data acquisition set-up of the flow cytometer. In our measurement the 
granulocyte signal was chosen as trigger for starting data acquisition. This means that 
data collection of a signal event starts only if a granulocyte is detected by the flow 
cytometer and lasts for a fixed time duration, i.e. a detection volume unit is defined. 
According to our mathematical considerations (Eqs. (8)-(10), see section IV/6/b) in 
such systems where only coincidence exists, proper transformation of double positive 
events results in straight lines with zero intercept. This is the case for the bead mixture 
(Fig. 28) which reassures us that, in our bead model, double positive events derive 
solely from coincidence. Transformation of platelet-granulocyte double positive data 
obtained for EDTA anticoagulated blood samples also gives straight lines (Fig. 30). 
Four of our seven donors exhibit zero intercepts in accordance with the literature 
describing no platelet-granulocyte complexes in the absence of Ca2+ (Hamburger and 
McEver 1990). However, it is noteworthy that three of our donors seem to have 
complexes (the intercept of their straight lines in Fig. 30 is significantly different from 
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zero), also in EDTA anticoagulated blood, indicating the existence of some Ca2+-
independent platelet-granulocyte complexes. Further investigation is needed to clarify 
this phenomenon. 
In citrated blood samples, platelet–granulocyte complexes are formed upon 
incubation at room temperature since citrate decreases but does not completely 
eliminates the Ca2+ concentration (Peters et al. 1997, Li et al. 1999, Peters et al. 1999, 
Hagberg and Lyberg 2000). Paraformaldehyde treatment of such citrated blood samples 
results in stable, dilution-independent platelet-granulocyte complexes. Transforming 
double positive data obtained for the paraformaldehyde-treated citrated blood (Fig. 32) 
can also be fitted with a straight line with a non-zero intercept, representing the amount 
of stable complexes (cf. Eq. (8), section IV/6/b). When platelet-bead double positivity 
was measured after mixing fluorescent beads into the same blood sample, 
transformation of the data resulted in a parallel straight line having a zero intercept (Fig. 
32). This indicates that coincidence has the same probability whether granulocyte or 
bead is the triggering signal, and the difference in the intercepts corresponds to the 
amount of real complexes. Thus the amount of platelet-granulocyte complexes can be 
calculated according to Eq. (12) (section V/2/b). 
The mathematical description of coincidence draws attention to the fact that the 
detection volume has a crucial impact on the extent of coincidence in a flow cytometer 
(cf. Eq. (8), section IV/6/b). The detection volume can be calculated from the technical 
data of the flow cytometer provided by the manufacturer. For the FACScan flow 
cytometer the estimated collection time period for fluorescence is 20 µsec. Considering 
the 1 µl/sec sample flow rate, the detection volume comes up as 20 pl. The same value 
(20.4±1.0 pl) was obtained within the limits of error when a mixture of the two non-
interacting fluorescent beads was analysed. In EDTA anticoagulated blood a 13.5±1.6 pl 
detection volume was found. This smaller value can be attributed to a lower sample 
flow rate, which is a consequence of about a four-fold higher viscosity of undiluted 
blood than that of the PBS. 
In the literature, various values were published (Peters et al. 1997, Jensen et al. 
2001, Bunescu et al. 2002, Pitchford et al. 2003) for the amount of platelet-granulocyte 
complexes measured in citrated blood samples of healthy donors ranging from 1.8% to 
25% in 416-fold (Jensen et al. 2001) and 15.2-fold dilutions (Peters et al. 1997), 
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respectively. Our findings may provide a possible explanation for the variation of data 
obtained in different laboratories. If the platelet concentration in the sample is not low 
enough, the contribution of coincidence to the measured amount of double positive 
events is no longer negligible, resulting in an overestimation of the platelet-granulocyte 
complexes. 
Based on our findings, we suggest three methods to avoid overestimation of platelet-
granulocyte complexes caused by coincidence if measured in a flow cytometer. The first 
possibility is that the contribution of platelet-granulocyte coincidence can be calculated 
when the detection volume and the platelet concentration are known (cf. Eqs. (8)-(10), 
section IV/6/b). Another possibility is to divide the blood sample into two parts: one 
part is stained for platelets and granulocytes, the other part is stained only for platelets 
and fluorescent beads are mixed into it. Then, by measuring platelet–granulocyte and 
platelet-bead double positivity at the same dilution (platelet concentrations need to be 
the same), the exact amount of platelet–granulocyte complexes can be calculated (cf Eq. 
(12), section V/2/b). The third and probably most practical method is to measure 
platelet-granulocyte complexes at dilutions high enough to make coincidence 
negligible. For measurement of the amount of platelet-granulocyte complexes upon 
incubation with nanoparticles, the dilution method was used.  
 
3. Prothrombotic effects of nanoparticles 
To use nanotechnology safely, one has to be aware of the possible hazards of 
nanomaterials. Previous research on biomaterials has shown that foreign materials in 
contact with blood induce thrombus formation. Moreover, investigation of air pollution 
has found that ambient nanoparticles, which can translocate from the lungs into the 
circulation, also exert prothrombotic effects. These scientific data suppose that 
manufactured nanoparticles may also influence haemostasis. Moreover, although nano-
sized particles are deposited mainly in the microcirculation, the effect of nanoparticles 
on microcirculatory thrombus formation has not been investigated yet. Hence our aim 
was to examine whether manufactured nanoparticles exert prothrombotic potential in 
small arteries and in the microcirculation.  
As in all toxicological studies, the choice of correct dosage is fundamental. We have 
chosen a concentration range that considers both of the following scenarios: (i) 
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manufactured nanoparticles are inhaled and translocate from the lungs into the 
circulation, and (ii) nanoparticles for medical use are directly injected into the blood. 
The background concentration of ambient ultrafine particles was found to be on average 
between 0.8 - 1.6 µg/m3 (1-5 x 104 particle / cm3) with peak concentrations reaching 
about 50 µg/m3 (3 x 105 particle / cm3) (Oberdorster 2001, Zhu et al. 2002). Similar 
concentrations were measured during the production of different manufactured 
nanoparticles: from 104 to 105 particle/cm3, however with much higher peaks exceeding 
1.2 x 106 particle/cm3 (Maynard et al. 2004, Brouwer 2010). Thus assuming 500 µg/m3 
peak ambient nanoparticle concentration in the air would result in 6000 µg nanoparticle 
exposure daily at a normal ~12 m3 air inhalation. Translocation of 10% of these inhaled 
nanoparticles (see section II/2/g) into the systemic circulation by a 70 kg person would 
result in about 0.01 mg/kg body weight concentration. A similar calculation was also 
used by Nemmar et al. to determine nanoparticle concentrations for their in vivo 
experiments (Nemmar et al. 2003a). Obviously nanoparticles injected directly into the 
blood circulation for medical applications might reach much higher concentration 
levels. Thus to cover a dosage range relevant for both exposure routes we applied a 
concentration range of 0.01-1 mg/kg body weight. 
First, prothrombotic effects of polystyrene bead nanoparticles were tested. These 
nanoparticles are used in many nanotoxicological studies as benchmark particles 
because they can be produced in different sizes with various surface modifications, and 
can be dispersed easily. In our experiments amine-modified polystyrene nanoparticles 
injected into the systemic circulation reduced and carboxyl-modified polystyrene 
nanoparticles increased the time until vessel occlusion was complete in small 
mesenteric arteries. Furthermore, amine-modified polystyrene nanoparticles activated 
platelets as indicated by the increased expression of platelet P-selectin and an elevated 
number of platelet-granulocyte complexes in whole blood. These results are in 
agreement with previously published observations (Nemmar et al. 2002b). Interestingly, 
the incubation of amine-modified polystyrene nanoparticles with platelets did not 
induce platelet aggregation in our experiments. These observations suggest that 
positively charged polystyrene nanoparticles provoke only modest platelet activation. 
Indeed, in a recent publication, amine-modified polystyrene beads were found to induce 
a non-classical way of platelet activation characterized by perturbation of the platelet 
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membrane (McGuinnes et al. 2011). This observation is supported by the findings that 
positively and negatively charged polystyrene nanoparticles change the fluidity of 
phospholipid membranes by altering the tilt angle of the phosphocholine head groups 
(Wang et al. 2008). Although polystyrene nanoparticles affected the cessation times in 
small mesenteric arteries, they had no effect on thrombus formation in cremasteric 
microvessels. The inconsistent results of the two thrombosis models might be explained 
by the methodical differences in the induction of thrombosis. In the cremaster model, 
light/dye-induced thrombosis was used which, in contrast to ferric chloride application, 
activates endothelial cells without endothelial denudation (Rumbaut et al. 2006). 
Moreover, another difference is that the microcirculation has, due to the higher ratio of 
endothelial cells to blood, a larger endothelial cell dependent antithrombotic capacity 
than the vessels of the macrocirculation (Esmon and Esmon 2011). 
Surprisingly, DEP failed to activate platelets or augment thrombosis in both small 
mesenteric arteries and in the microcirculation. These data are in contrast to previous 
findings demonstrating accelerated thrombus formation in large vessels after instillation 
(Nemmar et al. 2003a, Nemmar et al. 2003c, Nemmar et al. 2004) or systemic 
administration (Nemmar et al. 2007) of DEP. A possible explanation for these 
inconsistencies might be the different composition of DEP used in our study, or some 
changes in the physicochemical properties of nanoparticles during the dispersion 
procedure (sonication, interaction of nanoparticles with albumin). Missing 
prothrombotic effects upon DEP injection is also in contrast to our previous findings 
and to our recent investigations showing that carbon black, the main component of 
DEP, activates platelets, exerts prothrombotic effects and induces thrombus formation 
in the microcirculation.  
In addition, two different manufactured nanoparticles (TiO2 rutile and SWNT) were 
also tested in terms of the effect they exerted on platelet activation and thrombus 
formation. TiO2 (rutile) nanoparticles had no effect on platelet activation or thrombus 
formation in small mesenteric arteries or in the microcirculation. In contrast, TiO2 rutile 
nanorods increased ADP-induced platelet agglomeration in vitro and decreased the 
platelet count 24 hours after instillation (Nemmar et al. 2008). The distinct shape of the 
TiO2 nanoparticles might explain their different prothrombotic effects.   
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SWNT, the other nanomaterial tested, decreased thrombosis time in small 
mesenteric arteries. This result is in agreement with the findings of Radomski at al. 
(Radomski et al. 2005) who found similar effects of SWNT on thrombus formation in 
the carotid artery of rats. Interestingly, SWNT had a more pronounced effect in the 
microcirculation. The cessation time decreased dose-dependently upon the application 
of SWNT. Even as low as 0.01 mg/kg body weight concentrations of SWNT augmented 
thrombus formation. Although the cessation times were decreased, there was only a 
slight, non-significant decline in the onset times. These results indicate that platelet-
platelet binding or stabilisation of the thrombus rather than the initial platelet-
endothelial interactions have changed.  
To further analyse changes in platelet function upon exposure to SWNT 
nanoparticles, in vitro experiments were performed. SWNT increased P-selectin 
expression on platelets and induced a significant elevation in the number of platelet-
granulocyte complexes. The simultaneous change of these two parameters is consistent 
with earlier findings that P-selectin plays an essential role in the formation of platelet-
granulocyte complexes (Hamburger and McEver 1990). Aggregometry clearly detected 
a significant change in the optical density of PRP versus PPP upon the addition of 
SWNT to both samples. However, the shape of the platelet activation curve is unusual: 
the initial optical density increase, which represents platelet shape change at the 
beginning of the activation process, is missing, and the decrease in the optical density is 
also much slower than that induced by other platelet activators. Interestingly, the 
SWNT-platelet aggregometry curves published by Radomski and colleagues (Radomski 
et al. 2005) show the same unusual characteristics. This raises the question whether the 
change in optical density is a result of a typical platelet aggregation or whether platelets 
become connected to each other through SWNT strands. The aggregation of SWNT 
alone cannot explain the optical density decrease, as this was not detected in the control 
sample containing only SWNT in platelet-poor plasma. Similarly, Radomski at al. 
described platelet activation upon incubation with SWNT or MWNT. They also report 
the release of matrix metalloproteinases by SWNT-activated platelets which may further 
augment thrombus formation (Radomski et al. 2005). Semberova et al. found that Ca2+ 
influx by store operated calcium entry (SOCE, see also Fig. 7) plays an important role 
in MWNT-induced platelet activation and the subsequent release of platelet 
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microparticles (Semberova et al. 2009). Thus in our view SWNT might augment 
platelet aggregation by the direct activation of platelets, and by a mechanism where 
SWNT mediates adhesion between platelets.  
The most interesting observation of our study therefore is that SWNT exerts 
prothrombotic effects not only in small mesenteric arteries but also in the micro-
circulation. This finding is of particular importance because the microcirculation plays 
an essential role in various organ functions. Thrombotic events in the microcirculation 
reduce tissue perfusion and might result in functional disturbances.  
Summarising our results we can conclude that SWNT and amine-modified 
polystyrene beads activate platelets and induce prothrombotic effects in vivo. In 
contrast, DEP and TiO2 (rutile) nanoparticles as well as carboxyl-modified polystyrene 
beads do not activate platelets or induce thrombus formation. Moreover, carboxyl-
modified polystyrene beads prolong thrombus formation in small mesenteric arterioles. 
This means that no general judgement can be concluded on the prothrombotic effects of 
nanoparticles. Further data from the scientific literature corroborate this opinion. 
Prothrombotic effects of amine-modified polystyrene beads (Nemmar et al. 2002b, 
Silva et al. 2005, Mayer et al. 2009, McGuinnes et al. 2011), quantum dots (Geys et al. 
2008), gold (Deb et al. 2011), silica (Hudson et al. 2008, Tavano et al. 2010) and TiO2 
anatase (Haberl et al. 2015) nanoparticles, TiO2 rutile nanorods (Nemmar et al. 2008), 
TiO2 anatase nanotubes (Roy et al. 2007), CuO (Yu et al. 2010), carbon black 
(Khandoga et al. 2004, Radomski et al. 2005), DEP (Nemmar et al. 2003a), SWNT, and 
MWNT (Radomski et al. 2005, Semberova et al. 2009) have been published. According 
to the literature, no change in haemostasis was found in the presence of plain 
polystyrene beads (Nemmar et al. 2002b), gold (Dobrovolskaia et al. 2009), Ag, ZnO, 
TiO2 rutile, SiO2 nanoparticles (Haberl et al. 2015) or fullerenes (Radomski et al. 2005). 
Haemostasis was inhibited by nanoparticles isolated from calcified human and bovine 
tissues (Miller et al. 2009), silver nanoparticles (Shrivastava et al. 2009, Shrivastava et 
al. 2011), polylactic acid nanoparticles (Sahli et al. 1997), and carboxyl-modified 
polystyrene beads (Nemmar et al. 2002b). 
The striking differences in the haemostatic effects of nanoparticles indicate that all 
kinds of nanoparticles need to be tested to exclude any prothrombotic effects. To keep 
up with the rapidly developing nanotechnology and the production of new types of 
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nanoparticles, screening methods are necessary. We suggest that flow cytometry could 
be a method for screening platelet-activating effects of nanoparticles. The flow 
cytometric data were in correlation with in vivo prothrombotic effects, reliably detecting 
nanoparticles that augment thrombus formation. The flow cytometric measurement of 
platelet activation, completed with tests of coagulation and endothelial cell activation, 
could be the first line of screening methods to detect the prothrombotic potential of 
nanoparticles. 
Although the influence of nanoparticles on haemostasis has been discussed mainly 
from toxicological point of view, it can have therapeutic relevance too. Nanoparticles 
have been suggested for drug delivery applications. For effective drug delivery, 
however, drug-containing nanoparticles have to reach the target cells through the 
circulation. In this context, the microthrombotic effects of nanoparticles are relevant, 
because the trapping of nanoparticles by microthrombi may potentially reduce the 
availability of drugs and therefore result in therapy failure. Pro- and antithrombotic 
effects of nanoparticles have also been proposed in medical applications. Arg-Gly-Asp 
functionalized nanoparticles as synthetic platelets were recommended for early inter-
vention in trauma to halt bleeding (Bertram et al. 2009). TiO2 anatase nanotubes were 
suggested to control haemorrhage due to their enhanced coagulatory effect (Roy et al. 
2007). Structured alignment of nanoparticles can be used to provide superhydro-
phobicity and thus antithrombotic properties for biomaterials (Sun et al. 2005).  MWNT 
(Meng et al. 2005, Sun et al. 2005) were suggested as antithrombotic coatings for 
vascular grafts and stents.  
Thus in summary, we think that the studies conducted by us and others indicate that 
some ambient and manufactured nanoparticles have a thrombogenic potential which 
ultimately may exert detrimental health effects. In contrast, some other nanoparticles do 
not influence thrombosis or even have antithrombotic properties that might be useful in 
the development of non- or anti-thrombotic biomaterials. Screening the platelet-
dependent prothrombotic potential of manufactured nanoparticles might be carried out 
with flow cytometry. 
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VII. Conclusions 
 
1. Optimisation of the nanoparticle dispersion method  
To avoid creating coarse agglomerates when preparing dispersion of nanoparticles in 
physiological solutions, the following aspects were found to be important: 
i) Usage of a sonication energy high enough to deagglomerate the particles 
(>4.2 × 105 kJ/m3) 
ii) Addition of albumin or serum as stabilizers at a concentration sufficient to 
cover the nanoparticles (1.5 mg/ml HSA or an amount of serum resulting in 
a similar albumin concentration for dispersions with less than 0.2 mg/ml 
nanoparticle concentration) 
iii) The optimal sequence is first to sonicate the nanoparticles in distilled water, 
then to add the stabilizer, and finally to add buffered salt solution to the 
dispersion 
 
2. Optimisation of platelet-granulocyte complex measurement 
Based on our findings, we suggest three methods to avoid overestimation of platelet-
granulocyte complexes caused by coincidence in the flow cytometer: 
i) Calculate coincidence from the detection volume and platelet concentration, 
and correct the measured platelet-granulocyte double positivity with these 
data 
ii) Measure coincidence by adding fluorescent beads to the blood sample and 
correct the measured platelet-granulocyte double positivity with these data  
iii) Measure platelet-granulocyte complexes at dilutions high enough to render 
coincidence negligible 
 
3. Prothrombotic effects of nanoparticles 
Based on the investigation of ambient and manufactured nanoparticles on platelet 
activation in vitro and on thrombus formation in small arteries and in the 
microcirculation in vivo, we conclude that: 
i) Amine-, but not carboxyl-modified polystyrene beads induce activation and 
aggregation of platelets. Amine-modified polystyrene beads decrease and 
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carboxyl-modified polystyrene beads increase the time of thrombus 
formation in small arteries, but neither of them have an impact on thrombus 
formation in the microcirculation  
ii) DEP and TiO2 (rutile) nanoparticles injected into healthy mice have no effect 
on platelet activation or thrombus formation 
iii) SWNT induces activation and aggregation of platelets 
iv) SWNT exerts prothrombotic effects in small arteries as well as in the 
microcirculation 
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VIII. Summary 
The increasing technological and medical utilisation of manufactured nanoparticles 
necessitates the assessment of their risk to human health. Although ambient 
nanoparticles have been shown to exert prothrombotic effects, manufactured 
nanoparticles have been less well investigated in this regard. Moreover, although 
nanoparticles can also reach the microcirculation, prothrombotic effects of 
manufactured nanoparticles in the microvasculature have not been investigated yet. 
Thus the aim of our study was to characterize the effects of nanoparticles on platelet 
activation in vitro and on macro- and microcirculatory thrombus formation in vivo.   
In order to carry out our study, two methods, the preparation of particle dispersions 
and the measurement of platelet-granulocyte complexes, were optimised. To determine 
the prothrombotic effect of nanoparticles in vitro, platelet activation was measured by 
flow cytometry and aggregometry. In vivo thrombus formation was evaluated by 
intravital microscopy in small mesenteric arteries and in the cremasteric 
microcirculation of anaesthetised mice.  
Amine-modified polystyrene beads and SWNT, but not carboxyl-modified 
polystyrene beads, DEP, or TiO2 (rutile) nanoparticles induce platelet activation. 
Amine-modified polystyrene beads decrease and carboxyl-modified polystyrene beads 
increase the time of thrombus formation in mesenteric arteries, but neither of them has 
an impact on thrombus formation in the microcirculation. DEP and TiO2 (rutile)  
nanoparticles have no effect on platelet activation or thrombus formation, while SWNT 
induce activation and aggregation of platelets, and exert prothrombotic effects in 
mesenteric arteries, as well as in the microcirculation. 
Our studies strongly highlight the fact that some nanoparticles are thrombogenic in 
the macro- as well as in the microcirculation. Since prothrombotic effects cannot be 
estimated from the physicochemical parameters of the nanoparticles, screening methods 
would be necessary. 
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IX. Összefoglalás 
A mesterséges nanorészecskék növekvő technológiai és orvosi felhasználása 
szükségessé teszi ezen anyagok egészségügyi kockázatának felmérését. A környezeti 
nanorészecskék protrombotikus hatásai ismertek, ugyanakkor a mesterséges 
nanorészecskék ilyen hatásairól csak kevés adat áll rendelkezésre. Míg a keringésbe 
bekerülő nanorészecskék a mikrocirkuláció területeire is eljutnak, az itt kifejtett 
protrombotikus hatásokat még nem vizsgálták. Disszertációm célja ezért a mesterséges 
nanorészecskék vérlemezkeaktivációra, valamint a makro- és a mikrocirkulációs 
trombusképződésre kifejtett hatásainak vizsgálata volt. 
Mindehhez először két módszertani problémát oldottunk meg: a stabil 
nanorészecske diszperzió előállítását fiziológiás oldatokban, és a vérlemezke-
granulocita komplexek mérésének optimalizálását. A nanorészecskék in vitro 
trombocita aktivációra kifejtett hatásait áramlási citometriával és aggregometriával 
mértük. Az in vivo trombusképződést altatott egerek mesenteriális artériájában és a 
cremaster izom mikrocirkulációjában intravitális mikroszkópiával vizsgáltuk. 
Eredményeink azt mutatják, hogy az amin-módosított polisztirol nanogyöngyök és 
az egyfalú szén nanocsövek fokozzák a trombociták aktivitását, míg a karboxil-
módosított polisztirol nanogyöngyöknek, a dízelpornak és a titán-dioxid (rutil) 
nanorészecskéknek nincs ilyen hatása. A polisztirol nanogyöngyök amin módosítása 
csökkenti, míg a karboxil módosítás növeli a trombotikus elzáródás idejét a 
mesenteriális arteriákban, egyik módosítás sem befolyásolja azonban a mikrocirkulációs 
trombusképződést. A dízelpornak és a titán-dioxid (rutile) nanorészecskéknek nincs 
hatása a trombociták aktiválódására és a trombusképződésre, míg az egyfalú szén 
nanocsövek aktiválják és aggregálják a trombocitákat, valamint fokozzák a 
trombusképződést a mesenteriális arteriákban és a mikrocirkulációban is. 
Vizsgálataink ezek alapján felhívják a figyelmet arra, hogy egyes nanorészecskék 
mind a makro-, mind a mikrocirkulációban protrombotikus hatással rendelkeznek. 
Mivel ezek a hatások a nanorészecskék fizikokémiai paramétereiből nem 
kikövetkeztethetőek, szükség van e hatások szűrésére. 
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